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Natriuretic peptides (NPs) are a class of potent vasoactive peptide hormones, 
which maintain circulatory pressure/volume homeostasis through mediating 
vasodilation and decreasing vascular fluid volume. These regulatory peptides 
mediate their function through binding to membrane bound guanylyl cyclase 
receptors. There are three mammalian NPs, namely ANP, BNP and CNP that 
are well characterized. Snake venom NPs are structurally similar to 
mammalian endogenous NPs with a 17-residue ring but with C-terminal 
extension of varying lengths that confers altered biological activities. 
 Transcriptome of red-headed krait venom gland revealed the presence of a 
unique NP; called KNP. Structurally, this NP is distinct from mammalian and 
other venom NPs. It has a 38 residues long C-terminal tail in contrast to 4-6 
residues in mammalian NPs. Further, this tail has the propensity to form an α-
helix, unlike other NPs. This thesis documents the mode of action and 
structure-function relationships of KNP. 
KNP was heterologously expressed and purified from E.coli and its activity 
was assessed using in-vivo, ex-vivo and in-vitro assays. KNP induced 
relaxation of pre-contracted aortic strips in ex-vivo organ bath experiments by 
a mechanism independent of NP receptors. It induced vasodilation via 
endothelium-dependent pathways in contrast to ANP which mediated 
vasodilation via endothelium-independent mechanisms. In experimental 
animals, infusion of ANP caused a rapid drop in blood pressure which 
recovered within 30 min after the infusion was stopped. In contrast, KNP 
caused a sustained drop in blood pressure which did not recover within the 
experimental period (40 min). Also ANP caused a marked increase in urine 
 viii 
  
volume while KNP had no renal effects. These results showed that KNP 
exerted its biological activity through a different mechanism than canonical 
NPs such as ANP. 
The activities of various deletion mutants revealed the presence of two 
functional pharmacophores; the KNP Ring and the putative C-terminal helix. 
The ring functions like a classical NP while the putative helix induces 
vasorelaxation in an endothelium-dependent manner like intact KNP. Thus, 
the helical segment in the C-tail in KNP confers its function. The ring of KNP 
has receptor binding ability, but the presence of its tail blocked its interaction 
with NP receptors. Further, using various inhibitors, KNP was found to require 
nitric oxide, prostacyclins and hyperpolarization factor from endothelium to 
evoke vasodilation. 
KNP showed a remarkable resistance to degradation by neutral endopeptidase 
(> 150 min). Also, Ring of KNP showed increased half-life (12 min) 
compared to ANP (1.8 min). Using different mutants D3, R4 and D14 residues 
were identified to be responsible for the increased half-life of Ring.  
Thus this study has lead to the understanding of the mode of action of a unique 
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Chapter 1: Central role of natriuretic peptides – An 
Introduction 
1.1. Blood pressure regulation 
Blood flow is one of the vital processes for the survival of a vertebrate 
organism. Constant flow of blood ensures distribution of oxygen and nutrients 
to all tissues and organs. This is sustained by repeated, rhythmic contraction of 
heart, which pushes blood into the blood vessels for dissemination throughout 
the body.  Blood circulation is a pressure driven phenomenon, like any other 
fluid driven by a pump. The pressure in this system is due to the force exerted 
by blood on the walls of the blood vessel, commonly known as blood pressure 
(BP), defined by Ohm’s law of fluid dynamics (pressure = flow X resistance). 
Flow is directly dependent on the amount of blood that is squeezed into 
circulation by heart, called cardiac output (CO) and resistance depends on the 
contractile state of arteries and arterioles, called systemic vascular resistance 
(SVR).  
An array of stabilizing mechanisms such as neural, renal or humoral, modulate 
CO and SVR to keep BP within certain limits. Of these regulatory processes 
sympathetic nervous system (SNS) and kidneys play a major role. On a short 
time scale (seconds to hours), the variation in BP due to day to day activities 
(feeding, exercise, emotions, etc.) is effectively buffered by the SNS which 
senses the pressure changes with its afferent sensors (Sunagawa et al., 1998). 
Regulation of arterial pressure in hours or longer is heavily dependent upon 
the kidneys, which dictate fluid-electrolyte balance. 
Momentary changes in blood pressure are detected through three different 
sympathetic afferents, namely baroreceptors, thermoreceptors and 
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chemoreceptors, which sense pressure, temperature and oxygen levels 
respectively (Guyenet, 2006). Changes in these parameters result in an 
autonomic reflex feedback which signals heart and blood vessels to restore BP 
to its normal value (Guyenet, 2006). Within minutes to hours after a 
disturbance in BP, mechanisms that modulate fluid volume such as movement 
of intravascular fluid into interstitial space are activated. These short-term 
regulatory signals, reset the BP perturbation partly towards the normal level, 
but does not restore back completely to baseline (Hall et al., 2012). In such 
circumstances, long-term regulatory processes play a key role. Thought to be a 
kidney-centric phenomenon, long-term BP control alters body fluid volume 
through excretion to bring the system back towards baseline. Body fluid 
volume is determined by the balance between intake and excretion of salt and 
water (through kidneys, skin, gut and airways). Higher fluid volume imposes 
higher load on heart and hence, it is critical to maintain an appropriate salt and 
water levels to sustain normal BP. Thus, in response to rising BP, normally 
excretion of water and salts through the kidneys is increased. This regulatory 
mechanism is modulated by various hormonal and neural controls. Out of the 
exhaustive number of endocrinal secretions, renin-angiotensin-aldosterone 
system (RAAS) and natriuretic peptides (NPs) have influential roles. RAAS 
promotes sodium and water reabsorption and causes vasoconstriction. 
Excessive activation of this system elevates BP and circulating volume, which 
increases the transmural distending pressure experienced by cardiac muscles. 
This force exerted on the heart induces the production of NPs. These peptides 
cause vasodilation and increased excretion of water and salt as a part of a 
homeostatic negative feedback.  Thus, according to the Guytonian concept of 
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BP control, no disturbance can render a sustained alteration in BP unless the 
renal – pressure – volume relationship is reset.  
Pathophysiological state such as hypertension (HTN), the elevated BP 
increases stress on heart. It is one a major causes for cardiovascular, 
cerebrovascular and renal disorders like chronic heart failure (CHF), stroke, 
kidney failure etc., which are associated with high morbidity and mortality.  
Heart failure (HF) is a clinical syndrome, which is associated with impaired 
ability of the ventricles of the heart to fill (diastolic dysfunction) or eject 
(systolic dysfunction) blood (Yancy et al., 2013). It is estimated that about 5.1 
million in the U.S. have HF (Go et al., 2014) which accounts for 7% of total 
deaths due to cardiovascular disorders (Manickavasagam et al., 2009). HTN 
increases the risk of development of HF and is precedent in 75% of HF 
patients (Chobanian et al., 2003). Drugs with antihypertensive properties such 
as angiotensin converting enzyme inhibitors (ACEI), Angiotensin-II- receptor 
blockers (ARBs), β-blockers, Ca-channel blockers, diuretics, aldosterone- 
receptor blockers, vasodilators etc., have shown to decrease mortality due to 
HF (Manickavasagam et al., 2009). The potential strategies for 
antihypertensive therapy include, lowering CO and SVR along with increased 
urinary excretion of salt and water. Since multiple counter-acting mechanisms 
control BP, the antihypertensive action of a drug is evaluated not only based 
on its primary target but as well by its efficacy to regulate the compensatory 
processes. Table 1.1 lists the present targets for antihypertensive agents used 
for HF treatment. 
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1.2. Antihypertensive therapy  
1.2.1. Systemic hemodynamics as target 
1.2.1.1. Anti-adrenergics 
This class of drugs lowers the blood pressure by limiting the activity of 
neurotransmitters – epinephrine and norepinephrine. Activation of β1-
adrenergic receptors on the specialized conductive tissue of the heart by 
norepinephrine increases heart rate and contractibility. On the blood vessels, 
norepinephrine binds to α1-adrenergic receptors resulting in vasoconstriction 
(Del Bo et al., 1985). Circulating epinephrine binds to β2-adrenergic receptors 
on the blood vessels to stimulate vasodilation (Del Bo et al., 1985). 
Peripheral receptor blocking drugs belong to two major classes; β-blockers 
and α-blockers. These drugs prevent the neurotransmitters from binding to 
their receptor, thereby reducing heart rate and blood pressure (Stokes et al., 
1974). Owing to the negative inotropic effects and ability to cause 
bradycardia, β-blockers are not considered as the first-line medication in case 
of HF (Remme and Swedberg, 2001). However, current guidelines prescribe 
the use of β-blockers for systolic dysfunction only after stabilization using 
ACEI therapy (Dickstein et al., 2010). 
Apart from the peripheral receptor blockers, drugs that act on central and 
peripheral nerve fibers are in use. Centrally acting drugs such as clonidine and 
methyldopa prevent the stimulation of SNS in response to increased BP while 




1.2.1.2. Renin- Angiotensin inhibitors 
RAAS system produces potent vasoconstricting hormones, which induce the 
reabsorption of sodium and water through the kidneys. This system involves 
the production of angiotensin I (Ang I) from its precursor angiotensinogen 
through the action of renal protease renin. Further Ang I is proteolytically 
cleaved by angiotensin converting enzyme (ACE) to form the bioactive 
angiotensin II (Ang II). Ang II binds to its receptors AT1 to cause 
vasoconstriction in smooth muscles, increased reabsorption of water and 
sodium by the kidneys and synthesis of aldosterone by adrenal cortex. Thus 
the primary targets inhibited in this system are, drugs that block renin 
secretion, ACE inhibitors (ACEI), AT1 receptor blockers (ARB) and 
aldosterone receptor. These drugs are predominantly used for hypertension, as 
they are associated with marked decrease in SVR without significant change 
in CO, along with favorable renal effects (de Boer et al., 2003). ACEI therapy 
is recommended for patients with systolic dysfunction and is proven to have 
reduced mortality and hospitalization rate (Manickavasagam et al., 2009). 
ACEIs remain the first choice drugs with ARBs as alternative drugs in case of 
HF (Remme and Swedberg, 2001).   
1.2.1.3 Direct vasodilators  
These are drugs cause the relaxation of arteries. These drugs act quickly and 
are used in emergencies, as they are associated with potential hypotension and 
fluid retention. These drugs cause an elevation of cGMP in vascular smooth 
muscles. This increase in cGMP dilates blood vessels, which in turn cause 
reduction in arterial pressure, stroke volume and cardiac output (Kawakami et 
al., 1995). The current guidelines recommend the infusion of 
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Table 1.1. List of antihypertensive drugs and their targets 
 
Co: cardiac output, SVR: systemic vascular resistance 
 
Class of drug  Effect  Primary target  Examples of  drugs in market  
Centrally acting drugs  Reduce sympathetic neurotransmission  Cardiac and vascular 
sympathetic drive 







-  β-adrenoceptor 
blocker 
 
Antagonism of α- adrenoceptor  
 
Antagonism of β- adrenoceptor  
  
CO, heart rate, inhibition 
of renin release  
 
Prazosin and doxazosin  
Betaxolol , bisprolol  
ACE inhibitors Reduce formation of Ang II  SVR and water-salt 
reabsorption  
Captopril, enalapril, imidapril  
AT1 receptor blocker Blocks receptor subtype 1 of Ang II   SVR and water-salt 
reabsorption  
Irbesartan, candesartan cilexetil, 
Valsartan  
Vasodilators   Relax blood vessels SVR  Nitroglycerine, itramin, propatylnitrate ,  
Natriuretic peptides  
Ion channel modulators 
- Potassium channel 
openers 





Reduce intracellular calcium  
SVR and HR  
Nicorandil  
Verapamil 
Nifedipine, Felodipine, Amlodipine  
Diuretics  
- Loop  
- Thiazide  
- Potassium-sparing 
Block nephron  tubular sodium 
reabsorption  
Vascular fluid volume   
Furosemide, Bumetanide 
Metolazone, Indapamide 




nitroglycerin, nitroprusside or nestritide (B-type natriuretic peptide) in case of 
absence of symptomatic hypotension in patients with HF (Lindenfeld et al., 
2010). 
1.2.1.4 Ion channel modulators  
These drugs cause hyperpolarization of smooth muscles, which initiates 
relaxation. Potassium channel openers and calcium channel blockers are the 
potential drugs (MacGregor et al., 1987; Richer et al., 1990). These drugs 
cause an indirect elevation of cGMP by decreasing intracellular Ca
2+
 ions. 
Thus resulting in reduction in SVR, heart rate and stroke volume, which 
reduces BP. Calcium channel blockers such as Amlodipine and Verapamil are 
used for diastolic dysfunction (Manickavasagam et al., 2009).  
1.2.2. Kidney as target: Diuretics 
1.2.2.1 Loop and thiazide diuretics 
 
These are the oldest drugs, which have been used for antihypertensive therapy. 
These drugs aid elimination of water and salts by the kidneys. This process 
reduces fluid volume, and hence, lowering the load on heart thereby reducing 
BP. The diuretic drugs commonly target Na-K-2Cl cotransporters in different 
locations within the kidney. Loop diuretics prevent the reabsorption of sodium 
and chloride in the Henle loop of nephron while the Thiazide diuretics act on 
distal loop. Usage of diuretics is usually associated with potassium depletion, 
necessitating dietary supplements (Swedberg et al., 2005). This class of drugs 
is used only in patients with fluid overload as in pulmonary congestion or 
peripheral oedema and is usually given in combination with ACEIs (Remme 




1.2.2.2 Potassium-sparing diuretics 
  
Aldosterone antagonists or mineralocorticoid antagonists such as 
spironolactone and eplerenone inhibit the reabsorption of sodium by the 
collecting ducts of the nephron. These drugs interfere with the 
sodium/potassium exchange, thereby minimizing potassium excretion and 
weakly increasing water excretion (Epstein and Calhoun, 2011). These drugs 
are prescribed only to patients who have hypokalaemia when administered 
with ACEIs (Remme and Swedberg, 2001). 
1.3. Effects of antagonism of neuro-hormonal activation during 
HF 
During HF, the increasing stress on the heart activates the production of NPs. 
Despite the increase in plasma NP levels, the system exhibits resistance to 
their biological activity due to the exaggerated counter-regulatory neuro-
hormonal activation. Drugs used for the treatment of HF counteract the 
detrimental effects of these neuro-hormonal factors. Some of these drugs such 
as β-blockers, ACEIs, ARBs and spironolactone modulate the levels of 
circulating NPs (Richards et al., 2002) and increase their biological activity 
(Clerico et al., 2000). Treatment with certain ACEIs and ARBs like enalapril 
or candesartan or valsartan decrease the plasma levels of NPs which match the 
indices of reverse ventricular remodeling (Kasama et al., 2006). In response to 
certain β-blockers like carvedilol or bisoprolol, the hypotensive action of ANP 
is enhanced because of increasing plasma ANP and downregulation of 
processes that degrade the NP (van den Meiracker et al., 2003; Yoshimoto et 
al., 1998). Thus in retrospection to the findings it seems that the therapy for 
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HF targets a) the overactivity of counter-regulatory mechanism, which when 
abolished causes the NP levels to decrease, or b) a stimulatory effect of plasma 
NPs. Thus, levels of NPs during HF therapy serve as a prognostic tool (van 
Veldhuisen et al., 2013) as well as add on to the beneficial action of the drug. 
More recently, studies are focused on enhancement of the activity of NPs as an 
alternative approach for HF therapy. This goal has been attempted by 
administering exogenous NPs in healthy subjects and HF failure patients that 
has resulted in favorable effects (Schmitt et al., 2004). 
1.4. Natriuretic peptides 
Natriuretic peptides (NPs) are vital hormones participating in pressure/volume 
homeostasis in both health and disease. NPs counteract the blood pressure 
elevating effects of the RAAS by inducing vasodilation, natriuresis, diuresis 
and increasing endothelial permeability. Three decades of extensive studies on 
NPs have shed light on their molecular mechanisms, further extending to the 
understanding of its role in pathophysiological conditions.   
Marked reduction in blood pressure accompanied by increased water and 
sodium excretion, was observed for the first time when atrial extracts were 
intravenously injected into rats (de Bold et al., 1981). This seminal experiment 
progressed the understanding of the existing humoral link between heart and 
kidney. Subsequently, the factors involved in this regulatory process were 
identified and sequenced. These peptide hormones were called “Natriuretic 
peptides”. The first isolated peptide of cardiac origin was atrial natriuretic 
peptide (ANP) (Kangawa and Matsuo, 1984). Following which BNP and CNP 
were identified from brain (Matsuo and Kangawa, 1984; Sudoh et al., 1988; 
Sudoh et al., 1990; Ueda et al., 1987). These peptides have a conserved 17-
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residue ring with variable N- and C- terminal extensions (Matsuo and 
Kangawa, 1984) (Figure 1.1). The ring structure is held together by a 
disulphide bridge between two flanking Cys residues. This feature is shown to 
be essential for NPs to retain their biological activity (Olins et al., 1988). 
 In a system level, NPs exhibit smooth muscle relaxing ability and increased 
fluid-electrolyte excretion, which are associated with increased cGMP levels 
in different tissues (Waldman et al., 1984; Winquist et al., 1984). Following 
this observation, chemical cross-linking and pull down experiments led to the 
identification of the natriuretic peptide receptors namely NPR-A, NPR-B and 
NPR-C (Takayanagi et al., 1987). Among the three receptor subtypes A and B 
are linked to guanylyl cyclase (GC) (Chang et al., 1989). NP binding to these 
two receptors elevates cGMP levels. These receptors have ligand specificity; 
ANP and BNP bind to NPR-A (Suga et al., 1992) while CNP binds to NPR-B 
(Koller et al., 1991). The third receptor subtype C lacks the GC domain. NPR-
C is involved the clearance of NPs (Maack et al., 1987). This receptor can 
bind to all three NPs. Thus, a physiological response to a NP is mediated by 
specific receptors. 
1.4.1. Atrial natriuretic peptide (ANP) 
ANP is the first peptide to be isolated and characterized among the NP family. 
This peptide is majorly synthesized and stored in atria. RNA transcripts of 
ANP encode a 151-amino acid residue preprohormone (Kangawa et al., 1985) 
which is proteolytically processed to remove the N-terminal signal peptide to 
form 126-amino acid residue prohormone. Both prepro-ANP and pro-ANP are 
stored as dense granules in atrial myocytes. In response to atrial wall stretch or 
increasing transmural distending pressure in the cardiac chambers, secretion of 
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pro-ANP is stimulated (de Bold, 1985; de Bold et al., 1986), which is 
hydrolyzed by membrane-bound serine protease, corin, to release the bioactive 
28 amino acid residue peptide (Vuolteenaho et al., 1985; Yan et al., 2000). 
Other hormones such as endothelin, angiotensin and vasopressin also increase 
ANP secretion (Lachance et al., 1986). Mature ANP has a 6-residue long N-
terminal extension and a 5-residue long C-terminal tail flanking the 17- 
residue ring. In the kidney, alternately processed pro-ANP, results in a mature 
peptide with longer N-terminus extension, called urodilatin, which acts as 
local regulator of sodium-water balance (Forssmann et al., 1998).  
Upon entering the bloodstream, ANP circulates and acts via NPR-A in a 
number of tissues to cause vasodilation, decreased renal reabsorption of water 
and sodium, decreased release of renin and increased endothelial permeability. 
These responses reduce blood pressure and volume. Genetic knock out mouse 
model studies involving targeted deletion of ANP (-/-) or NPR-A (-/-) 
exhibited chronic arterial hypertension, cardiac hypertrophy and death (John et 
al., 1996; Oliver et al., 1997). This observation led to the understanding that 
ANP mediated NPR-A signaling has an important role in maintaining 
circulatory homeostasis.  
The plasma half-life of ANP is reported to be approximately 2 min (Yandle et 
al., 1986), with neutral endopeptidase (NEP) and NPR-C actively involved in 
the clearance of the peptide. NEP cleaves ANP between Cys7 and Phe8 
(Abassi et al., 1994), thereby linearizing the peptide, while NPR-C causes 
internalization mediated degradation on binding. Despite its rapid clearance, 
plasma levels of ANP increases to about 10-30 fold during pathophysiological 




Figure 1.1. Schematic representation of mammalian natriuretic peptides 
 All three isoforms have a 17-residue ring held by a disulphide bond ( ), with 
conserved residues shown in . These peptides differ in their C- and N-terminal 
extensions. ANP and BNP have 5 and 6 residues in their C-tail respectively, while 
CNP lacks tail. Variable residues within these peptides are represented in . 
 
1.4.2. B-type natriuretic peptide (BNP) 
BNP was first isolated from porcine brain tissue, but later found to be 
expressing in much higher concentration in cardiac ventricles of patients or 
animals undergoing cardiac stress such as congestive heart failure (Mukoyama 
et al., 1991). Hence, brain natriuretic peptide was renamed as B-type 
natriuretic peptide. Like ANP, BNP is synthesized as a preprohormone, which 
is cleaved by proteases to release a 32- amino acid residue functional peptide. 
Although BNP is stored in atrial granules along with ANP (Nakamura et al., 
1991), the mRNA level of BNP transcript is higher in ventricle compared to 
atria (Nakao et al., 1990).  BNP is not stored in ventricular tissues but is 
transcriptionally activated in response to wall stretch (Potter et al., 2009).  
BNP binds to NPR-A with 3.5 fold lower affinity compared to ANP 
(Kambayashi et al., 1990). Genetic knockout mice model studies involving 
targeted deletion of BNP do not result in observation similar to ANP deletion. 













































































instead shows ventricular fibrosis, with increased expression of angiotensin 
converting enzyme, transforming growth factor-β and pro-α-1 collagen – 
factors that promote fibrosis (Tamura et al., 2000). Although BNP signals 
through the same receptor as ANP, the knockout mice experiments suggest 
that they have distinct biological roles. Under physiological conditions, 
plasma levels of BNP are lower than ANP. Further, BNP has lower affinity to 
NPR-A compared to ANP (Bennett et al., 1991) and exhibits markedly lower 
vasodilatory potency (van der Zander et al., 1999). Thus, BNP is thought to be 
acting as a local paracrine antifibrotic factor within heart as fibroblasts express 
both NPR-A and NPR-B (Cao and Gardner, 1995). 
Plasma half-life of BNP is longer compared to ANP (20 min) (Holmes et al., 
1993). It has lower susceptibility to NEP hydrolysis and lower affinity for 
NPR-C. But during pathophysiological states such as congestive heart failure, 
its level elevates up to 200-300 fold (Mukoyama et al., 1991). In clinical 
practice BNP and its N-terminal propeptide (NT-proBNP) are used as a 
marker for acute heart failure and to monitor control of chronic heart failure 
(Cheung, 1994).  
1.4.3. C-type natriuretic peptide (CNP) 
The most abundant NP in brain, namely CNP was first identified from the 
porcine brain extracts (Sudoh et al., 1990). Later CNP was found to be widely 
expressed in endothelial cells. Synthesized as a preprohormone like the other 
two NPs, enzymatic processing of precursor CNP results in a 53-amino acid 
residue pro-CNP, which is abundantly found in tissues, while a shorter 22- 
residue CNP dominates in the circulation (Wu et al., 2003). Both the isoforms 
can interact with NPR-B and cause an elevation of cGMP. CNP is not stored 
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in granules, but secreted in response to a range of stimuli including growth 
factors and shear stress in endothelial cells (Suga et al., 1993).  
CNP levels in plasma are low (1-2 pM) under normal physiology, but are 
elevated during cardiac stress (Kalra et al., 2003). The elevated levels are still 
low compared to ANP/BNP during a pathophysiological condition. 
Pharmacological experiments show that CNP is a weak arterial vasodilator but 
potent venodilator compared to ANP and notably have no natriuretic effects 
(Barletta et al., 1998). Further CNP-deficient mice do not exhibit arterial 
hypertension. These observations suggest that CNP/ NRP-B system might not 
be as crucial as ANP/ NPR-A or NO/sGC systems in regulating vascular tone 
(Chusho et al., 2001). 
Interestingly, CNP signaling has anti-proliferative effects on endothelial cells, 
suggesting a possible inhibitory role in angiogenesis (Komatsu et al., 1996). 
Further CNP deletion in mice causes severe dwarfism and early death due to 
impaired endochondral ossification (Chusho et al., 2001). Thus, CNP is 
thought to be a paracrine and autocrine factor that exerts a major influence on 
growth and differentiation along with its role in maintaining vascular tone 
(Yamahara et al., 2003). 
1.5. Natriuretic peptide receptors (NPRs) 
Three subtypes of receptors have NP binding properties, namely NPR-A, 
NPR-B and NPR-C (Takayanagi et al., 1987). All three receptors exist as 
homo-dimers or -tetramers. These receptors have a large extracellular domain 
(~450 residues) and a single transmembrane region (~20 residues). Receptors 
A and B have large intracellular domains which include, the kinase homology 
domain (KHD), dimerization domain, and carboxy terminal guanylyl cyclase  
 16 
 
(GC) domain (Potter, 2005). Binding of NP to these two receptors leads to 
activation of GC, thereby increasing cGMP, the recognized secondary 
messenger of the NP system (Lowe et al., 1989). The third subtype, NPR-C, 
has 37 residues intracellular domain and lacks any GC domain.  
 
   
Figure 1.2. Schematic representation of natriuretic peptide receptors 
There are three isoforms of natriuretic peptide receptors, namely NPR-A, NPR-B and NPR-C. 
All three receptors exist as homo-dimers or -tetramers in their native state, with relatively 
similar exterior topology. NPR-A and NPR-B are linked to a guanylyl cyclase domain via a 
kinase homology domain (highly conserved between both receptors), while NPR-C lacks the 
GC domain. The intracellular region of NPR-C is a 37 amino acid residue segment. The 
percentages represent the extent of similarity between domains in different receptors. 
 
Hence, receptor-C is thought to be involved in regulating local concentration 
of NPs, by receptor-mediated internalization (Maack et al., 1987; Nussenzveig 
et al., 1990). Although, in the recent years, G-protein dependent down 
regulation of cAMP levels has been reported for NPR-C activation, its 
biological functions are unclear (Anand-Srivastava, 2005). 
1.5.1. Natriuretic peptide receptor-A (NPR-A) 
NPR-A is the primary receptor responsible for the bioactivity of ANP and 
BNP. It is expressed in different tissues including, kidney, lung, adipose, 

















The receptor oligomerizes as homodimers or homotetramers in a ligand 
independent manner in native state. The receptor binds to the ligand in 2:1 
stoichiometry with affinities ranked as ANP ≥ BNP >> CNP (Suga et al., 
1992). Sedimentation experiments show that dissociation constant Kd for the 
receptor dimer is ~500 nM which decreases to ~10 nM in the presence of 
ANP, suggesting that dimerization is favored in the presence of the ligand 
(Ogawa et al., 2010). 
The extracellular domain (ECD) contains three disulphide bonds and five N-
linked glycosylation sites, which are shown to be important for receptor 
function (Miyagi et al., 2000).  The ECD has a highly conserved chloride ion 
binding site near the dimerization interface. The binding of chloride ions is 
necessary for the activation of NPR-A. Further, ECD has a structurally 
conserved juxta-membrane motif, which links it to the transmembrane region 
(Huo et al., 1999; Ogawa et al., 2010). This motif consists of Pro-417, Cys-
423 (in disulphide bond with Cys-432) and Phe-425, conserved in all GCase 
(Miyagi and Misono, 2000). This segment is responsive to hormone binding 
and transmits the conformational change of ECD to intracellular domains.   
The kinase homology domain (KHD) in the inner side of the membrane is 
phosphorylated at four serine and three threonine residues in basal condition. 
Phosphorylation of the KHD is necessary for receptor activation, while 
dephosphorylation is a mechanism for desensitizing the receptor on prolonged 
exposure to ligand (Potter and Hunter, 1998). ATP has been shown to augment 
the activation of the GC domain on ANP binding (Kurose et al., 1987; 
Schroter et al., 2010), but the mechanism was unclear until recently. 
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Crystal structures of apo NPR-A and ANP bound NPR-A reveal the 
mechanism of receptor activation. The apo receptor structure shows certain 
hydrophobic interaction (Trp74 A with Trp74 B and Phe96 A with Phe96 B 
between monomers A and B) and hydrogen bonds (Asp71 A and His99 B, 
His99 A and Asp71 B) that holds the receptor as dimer (Ogawa et al., 2004; 
van den Akker et al., 2000). Upon ANP binding, all interactions at the 
receptor dimer interface except the [Phe96 A - Phe96 B] hydrophobic 
interactions are disrupted. ANP binds in an asymmetric fashion with N-
terminal segment interacting with monomer A and its C-terminal portion 
interacts with monomer B. This binding confers no significant change to the 
intramolecular distances, but largely affects the quaternary structure of the 
receptor. The receptor undergoes a twist motion that opens membrane distal 
region, while translocating the juxtamembrane motif in opposite direction; 
bringing them nearly 10 Å closer. This change in the orientation is thought to 
result in the movement of to the intracellular domains, which brings the GC 
domains in head to tail fashion. This rearrangement opens two GTP binding 
sites in the GC dimer, thus activating the receptor (Ogawa et al., 2004).  
ANP binding leads to activation of GC, which is further enhanced in the 
presence of ATP. Earlier ATP was thought to bind to KHD and allosterically 
augment the hormone-mediated response (Thorpe et al., 1996). But, recently, 
Potter et al., have shown that ATP competes for one of the GTP binding sites 
in the GC domain and decreases the Km of GTP in the presence of ANP 
(Robinson and Potter, 2012).  
Thus, activation of GC-linked NPR-A involves; hormone-induced structural 
changes of the ECD, which orients the GC domains in a head to tail fashion. 
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This conformational change results in the opening up of two GTP binding 
sites. ATP binding to one these sites allosterically enhances GC activity 
(Robinson and Potter, 2011, 2012). The hormone-bound domains of NPR-A 
lose their affinity for ligand, promoting its dissociation from the receptor. 
Finally dephosphorylation of regulatory sites in KHD desentisizes the 
receptor. The desensitization of NPR through dephosphorylation of KHD is 
stimulated on prolonged exposure to ANP/ BNP or by peptide hormone which 
have antagonistic role to NP, such as angiotensin, endothelin, basic fibroblast 
growth factor, etc. (Potter and Garbers, 1992).  
        
Figure 1.3. Model of NPR-A and NPR-B activation and desensitization 
The NPRs are thought to go through three states in the cycle of activation. These states have 
been represented as “basal”, “activated” and “desentisized”. Receptors in basal state are 
predominantly, dimers or tetramers, and are phosphorylated in 5 to 6 residues in their KHD 
domain. Grey color diamonds represent phosphorylated residues. The binding of NP to the 
inactive basal receptors induces a twist rotation of the ECD, which is transmitted 
intracellularly causing dimerization of GC domains. This process opens up two ligand pockets 
in GC, of which ATP (Black sphere) binds to one of the binding pockets and allosterically 
increasing affinity for GTP (grey sphere). Prolonged exposure to ligand causes 
dephosphorylation of KHD and results in the loss of affinity to NP. Hence, dissociation of NP 
from NPR and dephosphorylation of KHD domains desensitize the receptor.  The colors 
(grey: slower, black: faster) of the arrows between two receptor states represent the rate at 
phosphorylation or dephosphorylation. This model of NPR- A and NPR-B activation shows 













1.5.2. Natriuretic peptide receptor-B (NPR-B) 
NPR-B is the second GC- linked receptor of the NPR family. It is involved in 
CNP signaling (Koller et al., 1991). The overall topology of this receptor is 
similar to NPR-A. The ECD is 43% identical with disulphide bonds and 
potential glycosylation sites retained. The intracellular domains are 78% 
identical and phosphorylation sites are conserved in the KHD (Potter and 
Hunter, 1999). The ligand affinities are ranked as CNP >> ANP > BNP (Suga 
et al., 1992). The mechanism of activation of NPR-B is thought to be the same 
as of NPR-A. There are no structural studies on isolated NPR-B. This receptor 
is expressed in lung, ovary, adrenal, uterus and brain. NPR-B seems to be the 
predominant receptor in brain (Hirsch et al., 2003). Deletion of NPR-B in 
mice resulted in dwarfism, accumulation of white adipose tissue and infertility 
(Tsuji and Kunieda, 2005), suggesting CNP/NPR-B signaling to have key role 
in tissue remodeling, reproduction and brain functions (Lopez et al., 1997). 
Another study showed that transgenic rats expressing dominant negative 
mutation of NPR-B had cardiac hypertrophy providing a link between NPR-B 
signaling and cardiac growth.(Langenickel et al., 2006).  
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1.5.3. Natriuretic peptide receptor-C (NPR-C) 
The intracellular domain of this receptor lacks both KHD and GC, instead has 
a 37-residue peptide. Ligand binding exhibits no enzyme activity, but is 
thought to mediate certain cellular responses through inhibitory G-protein 
activation (Anand-Srivastava et al., 1996). All three NPs have high affinity for 
NPR-C with relative ranking of ANP > CNP > BNP (He et al., 2001). Unlike 
NPR-A and NPR-B, receptor subtype-C is known to bind to ring deleted 
analogs of ANP with higher affinity (Anand-Srivastava et al., 1990). Crystal 
structure of apo NPR-C and its complex with ANP, BNP and CNP are known 
(He et al., 2006). Comparison of these structures reveals the degeneracy 
versus specificity of hormone binding properties of different NPRs. 
Table 1.2. Affinity constants of ANP, BNP and CNP towards different 
NPRs 
  Dissociation 
constants  
 
Receptors  ANP      BNP  CNP  





2.6 pM  
7.3 pM
30 nM 
13 pM  
> 500 nM
7 pM 
10.8 pM  
Data as described in (Bennett et al., 1991) 
 The interaction interfaces in the complex crystal structure of the three NPs 
with NPR-C are almost identical, suggesting NPR-C uses a single 
conformation to bind to all three NPs, instead of adapting its local structure 
according to the differences in the ligand. Thus, the promiscuous nature of 
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NPR-C is attributed to its conformational rigidity in its binding sites (He et al., 
2006). 
Functionally, NPR-C is associated with clearance of these peptides; thereof 
controlling the amount of circulating NPs (Jaubert et al., 1999; Maack et al., 
1987). Internalization followed by degradation is the mechanism through 
which clearance occurs. NPR-C is the most abundant receptor among NPRs 
and it accounts for about 90% of total NPRs in important target tissues such as 
the kidney. NPR-C knockout mice show reduced ability to clear ANP, reduced 
ability to concentrate urine and lone bone overgrowth (Jaubert et al., 1999). In 
other words, animals lacking NPR-C, have exaggerated effects of NPR-A and 
NPR-B signaling leading to hypotension and gigantism. Thus, these results 
suggest that NPR-C is involved in clearance and possibly mediate other 
functions of NPs. In the recent years, binding of NP to this receptor has been 
associated with inhibition of adenylyl cyclase activity and activation of 
phospholipase C in a Gi protein dependent manner and causes a reduction in 
intracellular cAMP (Anand-Srivastava et al., 1996).  
1.5.4. Structure- function relationships of NP and NPR 
Several studies have looked into the structural requirement of a NP for binding 
to its receptor. Before the NPR-A –ANP crystal structure was solved different 
approaches were used to delineate important amino acid residues in ANP 
binding. Truncation of N- and C- termini extensions of ANP decreased the 
amount of cGMP produced in rat endothelial cells, suggesting that these 
segments influenced the interaction (Olins et al., 1988). Although deletion of 
the N-termini extension is tolerated, the C-terminal tail has profound influence 
on ANP activity.  
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The disulphide linkage within the peptide confers rigidity to the molecule.  
Disruption of the cyclic structure, reduces the affinity of the peptide to GC- 
coupled receptor by more than 1000 fold, thus it is an important structural 
feature associated with its bioactivity (Olins et al., 1988).  Although linearized 
NPs do not bind to NPR-A/NPR-B, they do bind to the non-GC coupled NPR-
C with high affinity (Bovy, 1990). Thus, linear ANP analog differentiated 
between GC and non-GC receptors (Anand-Srivastava et al., 1990). 
Alanine scan mutagenesis improved the understanding of the contribution of 
each residue to receptor binding. Residues F8, M12, D13, R14, I15, L21 and 
R27 had greater influence on receptor binding (Li et al., 1995). The structure 
of ANP by nuclear magnetic resonance gave further information about the 
solution structure of the peptide (Li et al., 1995). Using a structure based 
approach, ring minimization strategies were used to develop mini-ANP, which 
had 7.2 times lower affinity compared to wild type (Li et al., 1995). 
The crystal structure of ANP in complex with NPR-A gave clear molecular 
details of residue level interaction. ANP binds to NPR-A in an asymmetric 
fashion with N-terminal portion of the peptide interacting with one subunit 
while the C-terminal portion interacts with the other subunit. The structure 
reveals the key interaction between peptide and receptor, with R14 forming 
hydrogen bonds with D62B and E119A, F8 of ANP with a hydrophobic 
pocket created by Y154A, F165A, V168A and Y172A.  The third set of 
interactions is between N24 through F27 of ANP, which runs in partial β-sheet 
with receptor residues Q186B and F188B. These interactions perfectly 
correlated with the previous studies, thus identifying the key amino acids 
involved in ligand-receptor  interaction (Ogawa et al., 2004). 
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Figure 1.4. Intermolecular interactions of ANP with NPR-A 
Three crucial interaction sites between ANP and NPR-A are shown in the figure. (1) 
R14 of ANP is involved in hydrogen bonding with D62B and E119A of NPR-A. (2) 
F7 of ANP fits into a hydrophobic pocket constituting Y154A, F165A, V168A and 
Y172A. (3) The C-terminal residues of ANP, N24, S25, F26, R27 runs in parallel β-
sheet with Q186B and F188B. 
 
1.6. Physiological functions of NPs 
NPs are vital hormones that maintain circulatory homeostasis. Most of the 
known physiological response is due to interaction of NP with its NPR, which 
elevates intracellular levels of the secondary messenger cGMP. Hence, the 
downstream effectors that interact with cGMP determine the physiological 
response of the NP.  
cGMP is known to interact with three important protein targets. The first and 
principal mediator among these is a cGMP dependent protein kinase (PKG) 
(Schlossmann et al., 2005). Two different genes of PKG are known, of which 
PKG I, a cytosolic protein, which is expressed in cardiac myocytes, 
endothelial cells, brain, kidney and adrenal glands (Pfeifer et al., 1998). The 
second variant PKG II, a membrane bound protein, which is not expressed in 







(Pfeifer et al., 1996). Thus two PKG isoforms may be involved in mediating 
entirely different physiological response to NPs.  





cyclic nucleotide gated ion channels (Light et al., 1990). Although the specific 
channels modulated in response to NP binding are not known, it is evident that 
they are involved in NP mediated hyperpolarization and intracellular Ca
2+
 
decrease in vascular smooth muscle and inhibition of sodium reabsorption in 
the distal tubules of the nephron. 
The third group of proteins which bind to cGMP are the phosphodiesterases 
(PDE), which are crucial regulators of cGMP signaling (Rybalkin et al., 
2003). PDEs hydrolyze cyclic nucleotides to nucleotide monophosphates, 
thereby regulating their concentrations. NP-mediated cGMP increase has been 
shown to activate PDE 2, a specific enzyme that degrades cAMP. AngII 
causes an increase in intracellular Ca
2+ 
through cAMP, which activates PDE 3 
that degrades cGMP (Beavo, 1995).  
Thus PDEs play a major role in regulation and crosstalk of signals transmitted 
by both cAMP and cGMP (Figure 1.5).  
By triggering various cGMP-dependent cellular processes, NPs trigger 
vasodilation, natriuresis, diuresis, endothelial permeability and tissue 
remodeling which aids in the regulation of intra-vascular and total body fluid 
volume and blood pressure. 







Table 1.3. Physiological functions of natriuretic peptides 
Target 
system  




























•  Vasorelaxation (Brenner et al., 1990) 
•  Increased endothelial permeability (Sabrane et al., 2009; 
Skryabin et al., 2004) 
•  Decrease cardiac preload and after load (Shapiro et al., 
1986)  
 
•  Reduction of cardiac output (Breuhaus et al., 1985) 
•  Inhibition of cardiac remodeling (Kapoun et al., 2004) 
 
• Increase glomerular filtration rate by dilating afferent 
arterioles and constricting efferent arterioles (Harris et 
al., 1987a; Marin-Grez et al., 1986) 
•  Increased excretion of sodium by inhibiting proximal 
and distal tubule and collecting duct Na+ channels (Light 
et al., 1990) 
•  Induction of diuresis by inhibiting the incorporation of 
aquaporins (Harris et al., 1987b; Kishimoto et al., 1996) 
 
Suppress the production of : 
•  Renin- angiotensin- aldosterone (Richards et al., 
1988) 
•  Sympathetic nerve stimulation (Thoren et al., 
1986) 
•  Arginine vasopressin (Burrell et al., 1991) 
•  Endothelin(Hu et al., 1992) 
 
Inhibit growth factor induced cardiac hypertrophy and 
fibrosis (Cao and Gardner, 1995; Takahashi et al., 2003) 
 
1.6.1. Vascular and cardiac effects of NPs 
Predominant vascular effects of NPs include endothelial permeability and 
vascular smooth muscle relaxation. The exact mechanism by which NPs 
increase endothelial permeability is unclear. Genetic knockout mice with 
endothelial NPR-A deletion have raised BP (10-15 mmHg higher) and are 11-
13 % volume expanded compared to wild type animals, while animals with 
complete NPR-A knockout were severely hypertensive (30-40 mmHg) and are 
30 % volume expanded (Sabrane et al., 2005). Further endothelial NPR-A 
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knockout were not able to clear radio iodine labeled albumin in an ANP 
dependent manner in contrast to wild type animals (Sabrane et al., 2009). 
These experiments suggest that NP increases endothelial permeability to 
decrease intravascular fluid volume.  
NPs are potent vasodilators. These peptides cause the relaxation of smooth 
muscles via the activation of NPRs. In mice with complete NPR-A deletion, 
ANP do not cause relaxation of aortic strip in an ex-vivo system and exhibit 
no reduction in blood pressure in response to bolus injections of ANP 
(Holtwick et al., 2002; Lopez et al., 1997). The downstream signaling cascade 
of NPR-A activation that leads to muscle relaxation is well understood 
(Carvajal et al., 2000). It is a PKG dependent phenomenon, which leads to 
decrease in intracellular Ca
2+
, thereby inhibiting Ca
2+ 
dependent contraction. 
PKG opens big conductance calcium activated K
+
 channels, which facilitates 
hyperpolarization of the vascular smooth muscles (Alioua et al., 1998).  
Further, PKG phosphorylates inositol 3-phosphate receptor on sarcoplasmic 
recticulum which prevents the efflux of Ca
2+
 to the cytosol (Komalavilas and 
Lincoln, 1996). Subsequently PKG causes the phosphorylation of Ca
2+
 
sensitive targets such as myosin light chain which prevents the contraction 
(Nakamura et al., 1999). These cellular events lead to relaxation of the 
vascular smooth muscle (Figure 1.5), which counteracts the action of AngII, 
arginine vasopressin and α1- adrenergic stimulation. Further in an NPR-A 
dependent fashion, the synthesis of endothelin – a vasoconstricting peptide 
from the endothelial cells, is inhibited by NP (Hu et al., 1992). Thus, by 
inducing relaxation and inhibiting the secretion of opposing constrictor 
effectors, NP reduces blood pressures and volumes. This reduces intra-cardiac 
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volumes and pressures completing the negative feedback loop in association 
with decreased cardiac preload and afterload. 
 
 
Figure 1.5. NP signaling and degradation 
NPs signal by elevating intracellular cGMP levels. Three main protein targets that are 
activated or repressed by cGMP are Protein Kinase G (PKG), Phosphodiesterase 
(PDE) and cGMP gated ion channels. These protein targets are responsible for 
different physiological responses. PKG and PDE decrease intracellular Ca
2+
 levels 
and lead to phosphorylation of myosin light chain. This process aids the relaxation of 
smooth muscle. In the renal tubules cGMP directly as well as in PKG dependent 




 co-transported to prevent the reabsorption of 
Na
+
. Active degradation of NPs occurs through receptor-mediated internalization and 
hydrolysis by NEP. Circulating levels of NPs are maintained by these active 
clearance mechanisms. 
 
NPs exhibit antiproliferative effects on the site of its synthesis, the heart. Mice 
lacking ANP/NPR-A show cardiac hypertrophy (enlarged heart) while 
ANP/NPR-A overexpressing animals have smaller hearts (Holtwick et al., 
2002). This phenotype had an ambiguity of whether ANP/NPR-A signaling 
was directly involved in the growth inhibitory effects of cardiac myocytes or 
whether it is the response of high blood pressure when ANP/NPR-A is 
disrupted. In a study, mice lacking NPR-A were treated with anti-hypertensive 
drugs right from their birth (Holtwick et al., 2003). The elevation in blood 
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pressure was reduced while the cardiac overgrowth did not diminish 
supporting the fact that NP systems are involved in inhibition of cardiac 
myocyte growth.  
1.6.2. Renal effects of NPs 
Kidneys are an important target for long-term regulation of blood pressure as 
they play a key role in maintaining body fluid-electrolyte balance. In response 
to hemodynamic parameters, hormones and neuro-signals, the reabsorption of 
water and sodium is triggered (Kishimoto et al., 1996). Retention of sodium 
leads to blood volume expansion and this may result in cardiac overload. This 
phenomenon is counter regulated by NPs which vasodilate to allow 
accommodation of volume with little pressure rise and also inhibit 
reabsorption of water and sodium (Maack et al., 1986).  
NPs are involved in hemodynamic and glomerular changes in the kidneys. It 
exerts vasodilation of afferent arterioles whilst constrict the renal efferent 
arterioles, which increases intra-glomerular capillary pressure, glomerular 
filtration rate and filtration fraction (Marin-Grez et al., 1986; Potter et al., 
2006). These changes in the hemodynamics are accompanied by changes in 









 co-transporter and other Na
+
 channels (Light et al., 1990) 
preventing the reabsorption of sodium and inhibit the recruitment of aquaporin 
thereby increasing the water excretion (Harris et al., 1987b). 
Apart from the direct changes in reabsorption, NPs cause inhibition of renin-
angiotensin-aldosterone production. Increase in plasma ANP levels in a 
physiological context causes the inhibition of renin and aldosterone secretion 
(Chartier et al., 1984; Richards et al., 1988). At birth, NPR-A lacking mice 
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have higher levels of renin and aldosterone (Burnett et al., 1984; Shi et al., 
2001). The systemic levels of these factors decrease in adult NPR-A null mice, 
suggesting other compensatory mechanisms in response to elevated blood 
pressure might be in place (Shi et al., 2001).  
 
Thus by modulating intravascular fluid volume and pressure through different 
mechanisms, NP reduce cardiac load. 
1.7. Degradation of NPs 
The reported half-life of ANP in different species varies between 0.5-4 min 
(Yandle et al., 1986), with the organ preference for ANP extraction as lung> 
liver>kidney (Hollister et al., 1989). BNP in circulation is reported to have 
longer half-life (20 min) (Richards et al., 1993) while CNP has a short half-
life as that of ANP (2.6 min) (Palmer et al., 2009). Circulating NPs are 
continuously cleared by three main processes; (1) receptor-mediated 
internalization and degradation, (2) proteolytic inactivation and (3) secretion 
of peptide into urine or bile. Although not much information is known about 
the latter process, detailed studies have been conducted to investigate the 
mechanism of clearance via receptor and proteolysis.       
1.7.1. Receptor-mediated clearance of natriuretic peptides 
It is of immense interest that there exists an entirely separate receptor for the 
clearance of NPs – a unique mechanism in the cardiovascular system (Cohen 
et al., 1996). Receptor-mediated degradation mechanics of NPR-C involves 
clathrin-dependent endocytosis of the receptor followed by lysosomal 
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degradation of the peptide bound to the receptor and the recycling of the 
receptor back to the membrane(Nussenzveig et al., 1990). 
 NPR-C is a promiscuous receptor. It has lesser selectively for its ligand 
compared to NPR-A and NPR-B. Crystal structure of NPR-C with ANP, BNP 
and CNP has revealed that the receptor uses a single interface to bind to all 
three hormones (He et al., 2006). The structural rigidity imposed by the 
receptor forces the flexible ligand to adopt a conformation that would 
overcome the unfavorable entropic penalty (He et al., 2001). CNP bound to 
NPR-C takes up an extended conformation compared to ANP and BNP. The 
conformation of the different ligands utilizes different subset of residues 
within the receptor surface.  In comparison to NPR-A, NPR-C seems to have 
weak interaction with the C-terminal residues of ANP and BNP. Further subtle 
changes in the common binding pockets that interact with the residues in the 
ring between NPR-A and NPR-C have given insightful information about 
NPR-C’s degeneracy. Pocket I of NPR-C that interacts with F2 in the ring is 
more spacious compared to NPR-A to accommodate the side chain 
conformations of both ANP and CNP. Pocket II which interacts with residue 
at position 12 in the ring is shallower compared to NPR-A, providing less 
specific interactions which do not discriminate between the side chains in the 
three ligands.  
Isothermal titration calorimetry and radioligand binding studies gave CNP = 
ANP > BNP as the order of the NPs affinity to NPR-C, which matches their 
half-life data (He et al., 2001). 
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1.7.2. Proteolytic degradation of natriuretic peptides 
Neutral endopeptidase or Neprilysin (E.C.3.4.24.11) is a zinc dependent 
membrane bound metalloprotease which was identified as key player in the 
degradation of NPs (Stephenson and Kenny, 1987). This enzyme cleaves at 
the amino terminus of hydrophobic residues. Stephenson et al. have shown 
that the C7-F8 peptide bond is the first cleavage site during ANP degradation 
by NEP (Stephenson and Kenny, 1987). Cleavage of this bond results in 
opening up of the ring, which inactivates the peptide. Like ANP, CNP is 
efficiently cleaved by NEP, but BNP is a relatively poor substrate for NEP 
(Gerbes and Vollmar, 1990; Norman et al., 1991). The degradation profile of 
BNP shows cleavages sites located in the N- and C-terminal extensions and 
the bond between R14-I15 (Norman et al., 1991). The renal isoform of ANP, 
urodilatin, which has four extra residues on the N-terminus of ANP, is less 
susceptible to hydrolysis by NEP compared to ANP (Abassi et al., 1994).  
A familial mutation on ANP rendered a variant ANP with 17-residue long C-
terminal tail that showed an increased half life (Dickey et al., 2009). Thus the 
susceptibility of the known NPs to NEP may be ranked as CNP=ANP > 
Urodilatin >> BNP. These observations showed that the longer the N- and C-
termini of the NP, the less vulnerable it is to degradation. A possible 
mechanism for NEP mediated hydrolysis has been predicted using a modeled 
interaction site of NP with NEP (Pankow et al., 2009). Figure 1.6 shows that 
NEP interior cavity represented in light green, has two recognition sites R222 
and D372 opposite to the active site (depicted in yellow). NP slips into this 
pocket to orient the lytic bond (C7-F8) near the active site. It is thought that 
D13 and R14 of the NP interact with R222 and D372 of NEP electrostatically 
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to position the lytic bond. In the case of peptides with longer N- and C- 
termini, accommodation of the entire molecule within the pocket leads to 
spatial clashes, which confer resistance to cleavage (Pankow et al., 2009).  
Oral NEP inhibitors are shown to elevate plasma NP levels and increase 
sodium excretion during HF in various animal and human models (Wegner et 
al., 1995). Although NP levels in mice lacking neprilysin have not been 
reported, these animals do not show any obvious signs of increased NPR 
activation suggesting other degradation pathways compensating for the loss of 
NEP (Lu et al., 1995). 
  
 
Figure 1.6.  Hypothetical mechanism of NEP mediated hydrolysis 
A- Modeled active site of NEP. R222 and D372 of NEP binding pocket interacts with 
D13 and R14 of NP respectively, which aid the positioning of the lytic bond C7-F8 
near the active site. 
B- NP with short N- and C- terminal segments are accommodated with the active site 
while the ones with longer extension provide steric hindrance to be accommodated 
within the binding pocket which hampers the positioning of the lytic peptide bond.  
                   
NPs are also cleaved by another zinc metalloprotease called insulin-degrading 
enzyme (IDE) (Johnson et al., 1989). This enzyme is found in both 
cytoplasmic and membrane fractions and has a wide substrate specificity. It 
cleaves ANP at S25-F26 peptide bond in the C-terminal tail (Johnson and 




(Muller et al., 1992). Among the three NPs, ANP is the preferred substrate for 
IDE while BNP is relatively a poor substrate (Muller et al., 1992). In mice 
lacking IDE, amyloid-β protein and insulin levels are increased, but no record 
of NP levels are available (Farris et al., 2003). Hence, the physiological role of 
IDE in NP clearance is not clearly understood. 
The relative contribution of both NPR-C and NEP mediated degradation are 
equal for clearing NPs (Charles et al., 1996). It is thought that under 
pathophysiological condition where plasma levels of NPs are markedly 
elevated and NPR-C may be saturated, NEP plays a major role in degradation. 
Hence, strategies to improve half-lives of NPs pertain to increasing the N- and 
C-termini of these peptides or use of NEP inhibitors (Brandt et al., 1997).  
1.8. Pathophysiological role of NPs 
Increasing intravascular fluid volume due to higher water and sodium 
retention, a resultant of lowered cardiac output, is the phenomenon that 
provokes congestion of heart. The levels of NPs are the highest during such 
pathophysiological conditions (Rubattu et al., 2008). Despite the increase of 
NP, the exaggerated neuro-hormonal activation during cardiac dysfunction is 
not compensated. This apparent discrepancy has been attributed to one of the 
following reasons, but the exact mechanism is not understood yet: the release 
of non-active forms of NPs, increased clearance by proteolytic degradation, 
down regulation of NPRs, and increased antagonist mechanisms of RAAS, 
vasopressin and endothelin (Brockhoff et al., 2000). In view with this 
observation, BNP and its N-terminal propeptide (NT-proBNP) are used as 
diagnostic markers for the detection of HF in clinical practice (Anwaruddin et 
al., 2006; Cheung, 1994). Measurement of BNP and NT-proBNP is sensitive 
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and specific for the disease and is performed at a reasonable cost (Collinson et 
al., 2004). Several studies have observed a correlation between BNP and NT-
ProBNP levels and impaired left ventricular ejection fraction or systolic 
dysfunction (Gustafsson et al., 2005). Similarly, along with other diagnostic 
methods, level of NT-proBNP is used for detection of diastolic dysfunction 
(Lubien et al., 2002). Further, the plasma levels of these peptides are used for 
prognosis of treatment for HF. Among hospitalized HF patients, decrease in 
plasma levels of NT-proBNP indicated an improvement in their status 
compared to patients with no significant change or increase of NT-proBNP 
(Bettencourt et al., 2004). 
Also in experimental animals and healthy human volunteers, infusion of 
ANP/BNP resulted in marked reduction in blood pressure, increased 
natriuresis and diuresis, whereas in models and human with CHF renal 
responses were not as significant as normal subject but effectively contributed 
to the reduction in peripheral vascular resistance and blood volume (Burnett et 
al., 1986; Florkowski et al., 1994).  
1.9. Venom NPs 
NPs have been identified in all vertebrates. All these peptides have strikingly 
similar structures and are thought to have similar function. Apart from the 
well-studied mammalian NPs, other NPs from the venom of reptiles are new 
molecules with intriguing pharmacological functions. Venoms of snakes and 
lizards contain an ensemble of toxins, which are used for debilitation of prey. 
Venom NPs have similar 17- residue ring structure with variable N- and C-
termini. Certain peptides characterized from venom have distinct 
pharmacological action.  
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 The first NP from venom, identified from the green mamba snake, 
Dendroaspis natriuretic peptide (DNP) was reported in 1992 (Schweitz et al., 
1992). Since its discovery extensive studies have been done to investigate and 
compare this peptide from venom to the mammalian peptides. DNP possesses 
a similar 17- residue ring, but with a longer (14 residues) C-terminal extension 
compared to mammalian NPs. It relaxes pre-contracted aortic strips and 
induces cGMP response in rat aortic myocytes and endothelial cells equivalent 
to that of ANP (Schweitz et al., 1992). Through radiolabelled ligand studies, 
DNP has been shown to bind to NPR-A with a similar affinity as ANP, thus 
ranked as DNP = ANP > BNP > CNP (Singh et al., 2006). Despite the 
analogous properties of DNP to ANP, it shows 5-fold weaker binding to NPR-
C (Kd values: DNP 4.1 nM and ANP 0.8 nM) (Johns et al., 2007) and exhibits 
greater resistance to NEP hydrolysis (t½:  DNP > 150 min and ANP = 2.5 min) 
(Dickey and Potter, 2011). These distinct characteristics of DNP are attributed 
to its C-terminal tail. Further, infusion of DNP in dogs significantly reduced 
mean arterial pressure and caused natriuresis and diuresis effects together with 
an increase in plasma and urine cGMP (Lisy et al., 1999). Owing to the higher 
resistance of DNP to hydrolysis, the tail of DNP has been used to generate 
chimeric NP with CNP called CD-NP, which is attributed with potentially 
better clinical properties and is presently undergoing clinical trials (Lisy et al., 
2008).  
Since DNP, several NPs from snake venom have been isolated and 
characterized. Proteomic analysis of Macrovipera lebetina venom revealed the 
presence of two NPs in its venom, lebetin 1 and 2 (Bazaa et al., 2005). 
Although structurally similar to NPs, lebetins exhibited potent anti-platelet 
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activity (EC50: 100 nM) and the N-terminal extension of the peptide was 
identified as the region responsible for this activity (Barbouche et al., 1996). 
Following the identification of lebetin, a NP from Pseudocersates persicus 
called PNP was isolated. This peptide was shown to have both anti-platelet 
activity and NPR-A binding ability (Amininasab et al., 2004). PNP shares a 
similar N-terminal extension sequence as lebetin that is thought to explain the 
observation. Three isoforms of NPs from Oxyranus microlepidotus namely- 
TNP-a, TNP-b, TNP-c, have been identified (Ref). These peptides have longer 
C-terminal tails similar to DNP. Among three isoforms TNP-a and TNP-b, do 
not possess any vasorelaxation ability while TNP-c shows similar activity that 
of ANP and DNP (Fry et al., 2005). This difference in activity has been 
attributed to the presence of Pro residue replacing the conserved hydrophobic 
residue at the third position within the ring of TNP-a and TNP-b. 
In the following year, NP specific cDNA amplification from Australian 
elapids, Pseudonaja textilis and Pseudechis australis revealed the presence of 
several NP isoforms, of which Pt-NP-a and Pa-NP-c were recombinantly 
expressed and characterized. These two NPs, showed a weak interaction with 
NPR-A, despite their structural similarity. They exhibited a dose-dependent 
inhibition of angiotensin converting enzyme (ACE). These peptides have a Pro 
residue at position 5 within the ring, which may be attributed to the structural 
disruption responsible for weak receptor binding (St Pierre et al., 2006). 
In addition to the atypical NPs from elapids described above, recent studies 




ANP             MSSFSTTTVSFLLLLAFQLLGQTRANPMYNAVSNADLMDFKNLLDHLEEKMPLEDEVVPPQVLSDPNEEAGAALSPLPEVPPWTGEVSPAQRDGGALGRGPWDSSDRSALLKSKLRALLTAPRSL 
Mc-NP           MVGLSRLRGGG--LLLVLALLPLALD-GKPLE------EAPT------APSRIIPFSRPVRKQSQAVLDPMVHPERPAGSGDDGDSRRLEGLAKEALGDG------------------------- 
Mf-NP           MVGLSRLTGGG--LLLVLALLPLALD-GKPLE------EAPT------APSRIIPFSRPVRKESQAVLDPMVHPERPAGSGDDGDLSRLEGLAKEALGDG------------------------- 
KNP             MVGPSRLAGGGLLLLLLLALLPLALD-GKPAPPPQALPKDPA---AASAAERIMRALLPDSKSSRPATDRMVHPEHQAGGG---DTRRLQEPAKKGLLIS------------------------- 
Na-NP           MVGLSRLAGGG--LLLVLALLPLALD-GKPAP--EALHKPPTGLRTSLAALRILGYLRPDSKQSRAARDRMLHPEQQVGGGG—DSRPLQDETNKGKGSS-------------------------- 
                     
ANP             RRSSCFGGRMDRIGAQSGLGCNSFRY------------------------------------------------------- 151 
Mc-NP           ----CFGQRIDRICNVSGMGCNHVRTDP-----APT----ALARIIPFSRPVRKESRAALDRMQQPG-------------- 139 
Mf-NP           ----CFGLKLDRIGTSSGLGCNPKRPDP-----APT----ALARIIPFSRPVRKESRAALDRMQHPG-------------- 139 
KNP             ----CFDRRIDRISHTSDLGCRHRKDPPRAPPAAPSAAPLAVTWLIRDLRADSKQSRAA---------------------- 148 
Na-NP           ----CFGQKIDRIGSMSGMGCRTQGKPPPALPTAP-----AALRILEYLRPDSKRSRATRDRMLHPEQQVGGGGGGGSRVI 165 
                                      
 
B 
KNP              GLLISCFDRRIDRISHTSDIGCRHRKDPPRAPPAAPSAAPLAVTWLIRDLRADSKQSRAA 
ANP             SLRRSSCFGGRMDRIGAQSGLGCNSFRY 
BNP          SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH 
DNP             EVKYDPCFGHKIDRINHVSNLGCPSLRDPRPRPNAPSTSA 
TNP-a         SDSKIGDGCFGLPLDHIGSVSGLGCNRPVQNRPKK 
TNP-b         SDPKIGDGCFGLPLDHIGSVSGLGCNRPVQNRPKK 
TNP-c         SDSKIGNGCFGFPLDRIGSVSGLGCNRIMQNPPKKFSGE 
PNP      GENEPPKKKAPDGCFGHKIDRIGSHSGLGCNKFKPGH 
Na-NP       DETNKGKGSSCFGQKIDRIGSMSGMGCRTQGKPPPALPTAPAALR 
Pa-NPc     SGSKTAEIGDGCFGVPIDHIGSTSGMGCGRPRPKPTPGGS 
Pt-NPa        SGSKIGNGCFGLPLDRISNTSGMGCRNPIQNRPKSTPGGS 
 
Figure 1.7. Sequence comparision of KNP with mammalian and venom NPs 
A: Presursor NP found from the mRNA/ transcriptome of the following species Na–NP (ADK12001) from Naja atra, KNP (ADF50041) from Bungarus 
flaviceps, Mf-NP (AAZ39879) from Micrurus fulvius and Mc-NP (AAC60341) from Micrurus coralline have been aligned.     Signal peptide      Start of the 
mature protein      
B: Mature NPs from elapid snakes and human are aligned. TNP-a (P83226), TNP-b (P83229), TNP-c (P83231) identified from Oxyuranus species, PtNP-a 
(DQ116724) from Pseudonaja textilis, PaNP-c (DQ116727) from Pseudechis australia, Na–NP (ADK12001) from Naja atra, Mc-NP (AAC60341) from 
Micrurus coralline, DNP (AAB22476) from Dendroaspis augusticeps, KNP (ADF50041) from Bungarus flaviceps, ANP (AAA35529), Human BNP 
(AAH25785) and human CNP (NP_077720) have been compared.    Cys in disulphide bond       Evolutionarily conserved residues      Non- conserved, non- 




A number of viperids express CNP-like peptides along with multiple 
bradykinin potentiating peptides (BPP). BPPs inhibit ACE, the enzyme that 
degrades bradykinin. ACE inhibition has been one of the attractive targets for 
hypertension and captopril (the prototype ACE inhibitor preceding the array of 
ACEI, now in clinical use) is a peptidomimetic of BPPs (Murayama et al., 
1997). Although several viperids produce BPP-CNP, recent studies have 
shown the presence of ANP-like NPs from venoms of Crotalus durissus 
casacavella and Crotalus oreganus abyssus (Evangelista et al., 2008).  
Venom NPs exhibit an array of subtle changes compared with mammalian 
NPs that confer entirely different pharmacological effects. Exploring the 
activity of these peptides provide molecular details of specific NP action.  
1.10. Therapeutic potential of NPs 
Both ANP and BNP are produced by myocardial cells in response to 
increasing transmural distending pressure which is exaggerated during HF. 
These peptides activate NPR-A thereby increasing intracellular cGMP, which 
mediates natriuresis, inhibition of renin and aldosterone as well as 
vasorelaxation, anti-fibrotic, anti-hypertrophic and other effects (Ahluwalia et 
al., 2004; Potter et al., 2006). CNP through activation of NPR-B induces 
vasorelaxation, inhibition of vascular smooth muscle cell proliferation (Furuya 
et al., 1991), suppression of aldosterone (Wennberg et al., 1999) and 
prevention of cardiac remodeling, although it lacks significant natriuresis 
(Stingo et al., 1992). With such favorable cardiac and renal protection 
properties, NP system acts as a pivotal compensatory mechanism against the 
neuro-hormonal activation during HF (Lee and Burnett, 2007b). This gives a 
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strong justification for the use of exogenous NPs for cases of acute heart 
failure syndromes.  
Both ANP and BNP are clinically used. Human recombinant ANP 
(Carperitide) was approved in Japan in 1995 for acute HF (Gheorghiade et al., 
2005) and human recombinant BNP (Nesiritide) was approved in the U.S. in 
2001 (Lee and Burnett, 2007a). Table 1.4 lists the NPs, which are in use and in 
clinical trials for HF. 
Cody et al. and Saito et al. have demonstrated that intravenous infusion of 
ANP in patients with HF induced natriuresis, diuresis, inhibited the release of 
aldosterone, decreased systemic BP and pulmonary capillary wedge pressure 
(PCWP). But, they observed that the renal response was reduced in patients 
with HF compared to normal subjects (Cody et al., 1986; Saito et al., 1987). In 
a recent report on safety of using carperitide, an evaluation for a period of 6 
years with 3,777 patients who were treated with a median concentration of 
0.085 µg/kg/min of this synthetic peptide, 82% clinically improved (Abraham 
et al., 2005; Suwa et al., 2005). 
Infusion of BNP resulted in decreased PCWP and systemic vascular 
resistance, increased stroke volume index, increased urine volume and sodium 
excretion and decreased plasma aldosterone levels (Yoshimura et al., 1991). In 
the efficacy trials involving 127 HF patients, infusion of BNP resulted in 
decreased PCWP, improvement in global clinical status, reduced dyspnea and 
reduced fatigue (Colucci, 2000). Another study reported that BNP may worsen 
renal functions in patients with HF (Sackner-Bernstein et al., 2005). Thus a 
panel of experts have recommended the use of BNP only to patients with acute 
 41 
 
decompensated HF with dyspnea at rest and have suggested not to use BNP as 
diuretics.  
A challenge in the use of NPs is the route of administration. Owing the peptide 
nature, NPs are degraded in the gut with low oral bioavailability, thereby 
necessitating intravenous infusion or subcutaneous administration (Brunner-La 
Rocca et al., 2001; Chen et al., 2000). Newer long acting fusion hormones 
have been developed using BNP and human serum albumin called AlbuBNP, 
which have plasma half-life of 12-16 h (Wang et al., 2004).  Further infusion 
of BNP along with furosemide, a loop diuretic in HF animal models have been 
reported to exhibit natriuresis and diuresis, improved glomerular filtration rate 
and attenuation of aldosterone production compared to furosemide or BNP 
infused alone (Cataliotti et al., 2004). 
 


















































As described in (Lee and Burnett, 2007a) 
Apart from the usage of classical mammlain NPs, Burnett et al. have 
developed the concept of chimeric NPs. These NPs are designed to have N-
terminal and C-terminal extensions of a certain NP, while the ring of a 
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different NP, so as incorporate the properties of both peptides. Vasonatrin is a 
chimera of the CNP ring with the ANP C-terminal tail that exhibits 
vasodilation characteristic of both the parent NPs (Wei et al., 1993). A similar 
strategy has been used to develop CD-NP, a chimera of the CNP ring with the 
DNP 15-residue tail (Lisy et al., 2008). This chimera binds to both NPR-A and 
NPR-B (Dickey et al., 2008), attributes from the parent NPs, and hence was 
able to elicit venodilation, vasodilation, natriuresis and diuresis (Martin et al., 
2012). Although CD-NP had 60 times lower potency compared ANP and 
BNP, at pharmacologically relevant concentration, CD-NP retained its renal 
properties in an animal HF model (Lee et al., 2009). Also, this chimeric 
peptide is reported to have longer in-vitro half life (Dickey and Potter, 2011). 
This property CD-NP makes a promising therapeutic agent and is currently 
under clinical trials. 
Based on the existing studies, it is evident that NPs have favourable 
cardiorenal protection properties which could be put to use in the case of acute 
HF. However, further additional studies to elevate the efficacy and adverse 
effects of NPs are required to establish their effectiveness as pharmacological 
agents. Also, the discovery of NPs from non-mammalian sources add on to the 
knowledge, which would aid the creation of novel therapeutic molecules with 
improved pharmacological effects. 
1.11. Krait natriuretic peptide (KNP) 
The present thesis focuses on the characterization of a peculiar NP identified 
from krait. Kraits (Bungarus species) are large, highly venomous snakes 
inhabiting parts of south and South-east Asia. Predominantly nocturnal, these 
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reptiles feed on skinks, lizards, frogs, small mammals and snake eggs. A 
number of classical neurotoxins have been characterized from these species. 
Red-headed krait (Bungarus flaviceps), the species of krait from which the 
candidate molecule has been identified, has distinct body coloration, with a 
blue or black body and red colored head, neck and tail. The venom of B. 
flaviceps is more lethal than that of B. fasciatus and comparable to that of B. 
candidus. Except for a few neurotoxins isolated and characterized (Yanoshita 
et al., 2006), the venom of B. flaviceps is largely unexplored. A transcriptome 
analysis of the venom of this snake revealed the presence of several three-
finger toxins, neurotoxin and Kuntiz type serine protease inhibitors (Siang et 
al., 2010). Along with these a low abundant NP transcript was found. The 
identified NP transcript, namely KNP or Bf-NP (Krait natriuretic peptide) 
encodes a 148-amino acid residue protein with the first 27 residues predicted 
to be a signal peptide (Fig. 1.7A). The precursor has a long C-terminal tail (38 
residues); although it is similar in length to Micrurus coranillus (Mc-NP), 
Micrusus fulvius fulvius (Mf-NP) and Naja atra (Na-NP), it has a unique 
sequence (Fig. 1.7A). The C-tail of KNP has no sequence similarity against 
the non-redundant database on NCBI. The last 21 residues of the tail have the 
ability to form an α-helix when predicted using PSI-PRED. This propensity to 
form a secondary structure in the C-terminal extension has not been previously 
reported. Apart from the unique C-terminal tail, there are two substitutions of 
residues within the ring, which are conserved Gly residues in all other NPs.  
Thus with such unique characteristics, KNP may have different biological 
functions compared to all venom or mammalian NP characterized to date. 
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Figure 1.8. Schematic representation of ANP, DNP and KNP 
Compared to ANP and DNP, KNP has 38-residue long C-terminal tail with unique sequence. Last 21 
residues of the tail has propensity to form α-helix. Two evolutionarily conserved G residues (positions 3 
and 14 within the ring) are replaced by D in KNP. 
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1.12. Aim and scope of the study 
NPs from snake venom have distinct biological characteristics. Understanding 
their biological functions has lead to the design of newer and better 
pharmacological agents. To date, few venom NPs have been isolated and 
characterized.  Hence, exploration for novel NPs from an exogenous source as 
snake venom, will serve in understanding the diversity of NPs and design of 
NPs with therapeutic potential. 
The transcriptome of the venom gland of Bungarus flaviceps revealed the 
presence of a NP with a long C-terminal tail, “KNP”. This peptide has a 
unique sequence with a propensity to form α- helix in its C-terminal segment. 
Also, Gly residues at positions 3 and 14 within the ring that are conserved in 
all other NPs, are replaced by Asp in case of KNP. Hence, this thesis focuses 
to understand the mode of action of KNP using structure-function 
relationships of the molecules. The objectives of this thesis are: 
 
1. To document the biological function of KNP 
 Heterologous expression and purification of KNP 
 Evaluation of vasodilator actions of KNP 
 Evaluation of in-vivo activity of KNP: effect on blood 
pressure and urine output  
 
2. To delineate the mechanism of action of KNP 
 Assessment of structure- function relationships 




3. To investigate the stability of KNP to degradation 
 Role of residues involved in conferring resistance to 































Tail wags the dog: C-terminal tail redirects KNP 

















Chapter 2: Tail wags the dog: C-terminal tail redirects 
KNP away from natriuretic peptide receptor 
2.1. Introduction 
Snake venoms are a cocktail of pharmacologically active proteins. They have 
evolved to aid prey capture and deterrence. These protein toxins target 
different physiological systems resulting in neuromuscular and respiratory 
paralysis, loss of consciousness, hemorrhage, localized pain etc., in their prey 
(Gaffney et al., 1979). In the last few decades, with the advent of specialized 
techniques a number of toxins have been identified. One such toxin, identified 
from the venom gland of red-headed krait (Bungarus flaviceps) named Krait 
natriuretic peptide (KNP), is investigated in the present study.  
B. flaviceps is a highly venomous elapid snake found in South and Southeast 
Asia. Transcriptomic analysis revealed the presence of a full length precursor 
NP (Bf-NP or KNP) (Siang et al., 2010). KNP has a 17-residue ring as have 
all known NPs. However the 38-residue long C-tail is the longest such tail 
known among NPs. In-silico analysis suggest the C-tail has propensity to form 
an α-helix (Figure 1). The amino acid residues of the C-tail of KNP are 
unique. Further, Gly residue at positions 3 and 14 which is conserved within 
the ring of all NPs has been substituted with Asp residue in KNP. With 
distinct features – unique sequence, propensity to form α-helix and 
possessing much longer C-tail than any known NP – KNP is hypothesized 
to exhibit a distinct biological actions.  The unusual C-terminal makes KNP 
an interesting candidate to evaluate its function. KNP showed an endothelium-
dependent vasorelaxation, in contrast to classical NPs. Infusion of KNP in 
experimental rats resulted in sustained and prolonged decrease in blood 
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pressure and heart rate while did not influence the renal function in contrast to 
ANP. These observations connote the existence of a unique mode of action for 
KNP. A structure based functional studies revealed the putative helix region to 
be involved in conferring this action. 
2.2. Materials and Methods   
2.2.1. Materials 
Materials used in the experiments described below were obtained from the 
following sources: 
Codon optimized Synthetic DNA of KNP cloned in pUC-57 from Genescript 
corporation (Piscataway, NJ, USA), pET-32a vector (Novagen, Merck 
biosciences), DNA oligos for amplification from1
st
 Base Asia (Singapore), 
Hifi polymerase (Kapa Biosystem, Cape Town, South Africa), Kpn1 and Sac1 
restriction enzymes (Fermentas Fast Digest, Ontario, Canada), QIAquick gel 
extraction kit (Qiagen, Hilden, Germany), T4 DNA fast Ligase (Fermentas, 
Canada), DNA Gene ruler (Fermentas, Ontario, Canada), plasmid extraction 
kit  (GeneAll plasmid miniprep kit, Korea), Big Dye (Life Technologies, 
Carlsbad, USA), Luria burtani- broth and agar (Q.BIOgene,Irvine, CA, USA), 
Precision Plus Protein™ Dual-Colour Standards (Hercules, CA, USA), 
Acetonitrile and trifluoroacetic acid, Formic acid (Merck KGaA,Darmstadt, 
Germany), RP- Jupiter C18 columns ( 300 Å, 5 μm, 250 mm X 21.2 mm and 
250 mm X 10 mm) from Phenomenex (Torrance, CA, USA), Hiprep 26/10 
desalting column and Hi-Trap-Sulfopropyl (SP)-Sepharose column (GE 
healthcare, Little chatfont, UK), Tris-HCl, Urea, NaCl from 1
st
 Base Asia 
(Singapore, Singapore), TGA, TGR, pre-loaded Wang resin (Novabiochem, 
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Merck chemicals, NY,USA), Fmoc-protected amino acids (Anaspec, China, 
Novabiochem or GL Biochem, China), Solvents N-N-dimethylformamide 
(DMF), Dichloromethane (DCM), piperidine, N-methyl pyrrolidine (NMP), 
N-N-diisopropylethylamine (DIPEA), 1,2-diethylether, methanol, Acetonitrile, 
trifluroacetic acid and formic acid (Merck chemicals, NY, USA). 
 
CHO-K1 cell line (American Type Culture Collection,Manassas, VA, USA), 
L-NAME,Indomethacin, Dulbecco's Modified Eagle's Medium (DMEM), 
IBMX, BSA (Sigma-Aldrich ,St. Louis, MO, USA), Penicillin-Streptomycin, 
Trypsin and trypsin neutralizer (GIBCO, Invitrogen, CA, USA), ODQ 
(Cayman Chemical,Ann Arbor, MI, USA), Tissue culture plates (Corning, 
NY, USA), saline, heparin (5000 IU/ml), sodium pentobarbital (NUS, 
pharmacy, Comparitive medicine). 
Animals 
Animals (Sprague Dawley rats) were obtained from  Invivos and acclimatized 
in the Comparitive Medicine, Animal Holding Unit for a minimum of one day 
before the experiments. The animals were kept under standard conditions with 
food and water available ad libitum in a light-controlled room (12 h light/dark 
cycle, light on 07:00 h) at 23°C and 60% relative humidity.  
2.2.2. Cloning of KNP and deletion mutants 
The DNA sequence encoding KNP was optimized for expression in 
Escherichia coli and synthesized. Obtained synthetic gene was cloned in 
pUC57 vector. This fragment was amplified using forward primer 5’ 
GGTACCGAAAACCTGTACTTCCAATCGGGCCTGCTGATTT 3’ which had 
Kpn1 restriction site followed by  tobacco etch virus (TEV) protease 
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recognition sequence followed by the 5’ end of the gene of interest and reverse 
primer 5’GAGCTCTTATTAATGCGGCACGGCTCTGTTTACTATC3’ which had 
complementary sequence to 3’ of the gene and Sac1 restriction site. Synthetic 
DNA (0.1 μg) containing plasmid was mixed with 1 μl of 10 μM primer stock, 
1 μl of 10 mM dNTPs, 1 unit of Kapa HiFi polymerase and 10 μl of  5X PCR 
buffer containing MgCl2 in a 50 μl reaction. The cycling parameters were set 
as one cycle of 98ºC for 2 min, 35 cycles of 98ºC for 10 s, 60ºC for 30 s and 
72ºC for 45 s, and a final extension at 72ºC for 7 min. The amplified product 
was analysed using 1% (w/v) agarose gel electrophoresis. The obtained 
product was extracted from gel using the Qiagen gel extraction kit using 
manufacturer’s protocol.  
Both the DNA fragment and pET-32 a (vector into which the DNA fragment 
is to be cloned) were double digested using Kpn1 and Sac1 enzymes (1 unit 
enzyme per μg DNA) for 30 min at 37°C. Digested pET-32a was run on 1 % 
(w/v) agarose gel and band corresponding to the linear plasmid was extracted 
from the gel. The double digested DNA fragment of KNP was subjected to 
PCR purification. Concentrations of the purified digested DNA fragment and 
the vector were determined by measuring using NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies) with software ND-1000 V3.3.0. 
Insert and vector were ligated at 3:1 molar ratio. To the DNA mixture, 1 unit 
of T4 DNA ligase along which the 2 μl of 5X ligase buffer was set up for a 
reaction of total volume 10 μl and was incubated 4°C overnight. 
2.2.3. Preparation of competent cells and transformation 
Before transformation, the competent cells for E. coli JM109 (copy number 
increase strain) and BL21DE3 (expression strain) were prepared. The stock of 
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these cells was thawed and streaked on LB agar plates without any antibiotic 
and was grown at 37°C for 16 h. The following day, a single colony from plate 
was inoculated in 2 ml of LB broth without any antibiotics and was culture at 
37°C, 200 rpm, 16 h. 1 ml from the overnight culture was used to inoculate 
100 ml of LB broth without any antibiotic and was grown until the optical 
density at 600 nm reached value between 0.6-1 OD at 37°C, 200 rpm. The 
culture was transferred to an ice-cold falcon tube and spun at 2000 g, 4°C for 
10 min. The culture supernatant was discarded and the cells were resuspended 
in 1 ml of 100 mM CaCl2 which was further diluted to 50 ml with the same 
solution. This mixture was incubated on ice for 40 min, following which it 
spun at 2000 g, 4°C for 10 min. The cell pellet was gently resuspended in 8-10 
ml of 100 mM CaCl2 containing 10% glycerol (sterilized) and was split into 
pre-chilled 1.5 ml Eppendorf tubes as 50 μl aliquots. 
The prepared competent cells were used for transformation. A vial of the cells 
was thawed on ice and the ligation mixture was added to it and incubated on 
ice for 30 min. After the incubation, the cells were subjected to heat shock at 
42°C for 90 sec and were immediately transferred on ice for 5 min. This was 
followed by the addition of 200 µl of LB broth and recovery of cells by 
incubating at 37°C, 200 rpm for 30 min. This transformation mixture was 
spread on LB agar plate containing 100 µg/ml ampicillin. The plates were 
incubated at 37°C for 16- 18 h. 
2.2.4. Plasmid isolation and DNA sequencing 
Isolated transformants for the plates were inoculated in 2 ml LB broth 
containing 100 µg/ml ampicillin and cultured for 16 h at 37°C, 200 rpm. 





plasmid extraction kit, using protocol recommended by the manufacturer. The 
concentration of DNA was measured as described previously. 
DNA sequencing of the plasmid was performed using ABI PRISM® Big 
Dye™ Terminator Cycle Sequencing Ready Reaction Kit (version 3.0) (PE-
Applied Biosystems, CA, USA). Each reaction contained 100 ng of plasmid 
DNA which was mixed with 2 µl of Bigdye and 1 µM T7 promoter or 
terminator primers in a volume of 5 µl. The reactions were amplified using the 
following cycling conditions: 25 cycles of denaturation at 96ºC for 10 s, 
annealing at 50ºC for 5 s and extension at 60ºC for 4 min. The PCR product 
was cleaned using Cleanseq magnetic beads and the purified DNA was 
dissolved in 40 µl of autoclaved water. This DNA mixture was loaded on to 
automated ABI PRISM® 3130XL Genetic Analyzer (Applied Biosystems, 
Foster City, CA, USA). The obtained sequences were analyzed using FinchTV 
and Generunner softwares. 
 
2.2.5. Expression of KNP  
After verifying the sequence, clones encoding the fusion protein were 
transformed into E. coli expression strain BL21 DE3 as described previously.  
A single colony was inoculated in 100 ml LB Broth containing 100 µg/ml of 
ampicillin and grown for 16 h at 37°C at 200 rpm. This culture was used to 
inoculate 1 l LB broth containing 100 µg/ml ampicillin in 1: 100 (culture: 
broth) ratio and was growth at 37°C, 200 rpm until the cell density reached ~ 
0.6 OD at 600 nm. Protein expression was then induced using 0.1 mM IPTG 
(isopropyl β-D-thiogalactoside) and further grown at 16°C, 150 rpm for 16-18 
h. The cells were harvested by spinning them at 5,000 g for 15 min at 4°C. 
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The cell pellets were stored at -80°C until further processing. The expression 
of recombinant protein was analyzed using SDS-PAGE on a 15% 
polyacrylamide gel. 
Bio-Rad Mini-PROTEAN™ gel system was used for running SDS-PAGE. 
Samples were prepared by mixing 20 µl of sample and 5 µl of 5X loading dye 
and incubating the mixture at 100°C for 10 min. The samples were spun at 10, 
000 g and 10 µl of this mixture was loaded on to the gel. On the first lane 
molecular weight ladder, Precision Plus Protein™ Dual-Colour Standards (5 
µl) was run. Electrophoresis was carried at 120 V until the dye front reaches 
the bottom of the gel. The gel was stained with Coomassie Brilliant Blue-
R250. 
2.2.6. Purification of KNP 
To purify the expressed protein, the harvested cells were resuspended in native 
lysis buffer (50 mM Tris-HCl, 150 mM NaCl pH 8) and were subjected to 
ultrasonication (pulse frequency 1 s ON and 1 s OFF) for 5 min. The lysed 
cells were spun at 12,000 g and pellet was washed with wash buffer (50 mM 
Tris-HCl, 150 mM NaCl, 2 M urea pH 8). The slurry was spun at 12,000 g and 
the pellet was solubilized in denaturation buffer (50 mM Tris-HCl, 150 mM 
NaCl, 8 M urea pH 8) overnight at 4°C. After the solubilizing the protein 
solution was spun at 12,000 g to remove particulate matter. These samples 
were run on SDS-PAGE to assess the presence of the protein. Hence, the 
crude protein mixture from the solubilized pellet was syringe filtered and 
purified by reversed-phase chromatography using Jupiter C18(5 µm, 300 Å, 
250 X 21.2 mm ) preparative grade HPLC column using 0.05 % formic acid 
(FA) as buffer A and 100 % acetonitrile with 0.05 % FA as buffer B on Akta 
 55 
 
purifier system (GE Healthcare Life Sciences, Little Chatfont, UK). A linear 
gradient of 40-70 % B was used to achieve required separation of the protein 
peaks and the quality of the fusion protein was analyzed using Electrospray-
ionization (ESI) - Mass Spectrometer (MS) (LCQ Fleet Ion trap, 
Thermoscientific, Massachusettes, USA). Mass analysis involved injection of 
25 µl of the sample at 200 µl/min flow rate into the ion source. Sheath gas 
flow rate of 30, auxillary gas flow rate of 5 at a spray voltage of 4.5 KV and 
capillary temperature of 350°C was used for ionizing the sample. The ion-trap 
detector was set in positive mode with a mass/ charge range of 500-2000. Qual 
browser, Thermo Xcalibur software was used analysis and Pro-mass software 
(Thermoscientific) was used for reconstructed the mass spectrum. The 
fractions which showed pure protein mass were freeze dried. 
 The freeze dried fusion protein was dissolved in 50 mM Tris-HCl, 150 mM 
NaCl, 6 M urea pH 8 and desalted using 50 mM Tris-HCl pH 8 buffer using a 
Hiprep 26/10 desalting column (26 mm X 100 mm). The desalted fusion 
protein was cleaved using recombinantly expressed and purified TEV protease 
in the ratio 40:1 (fusion protein:TEV) in 50 mM Tris-HCl containing 0.5 mM 
EDTA pH 8, overnight at 4ºC.  
The predicted pI of KNP is 10.67 while the corresponding pI of the fusion 
protein and tag were 6.82 and 5.79 respectively. Hence, the difference in their 
pIs was exploited to purify the cleaved protein from the tag and uncut fusion 
protein. Cation exchange chromatography (CIEX) was performed with 50 mM 
Tris-HCl pH 8 as buffer A and 50 mM Tris-HCl, 500 mM NaCl pH 8 as buffer 
B, on a Hi-Trap-Sulfopropyl (SP)-Sepharose column (34 μm, 16 X 25 mm). 
Further the cleaved protein peak was purified to homogeneity using RP-HPLC 
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with Jupiter C18 column (5 µm, 300 Å, 250 mm X 10 mm) with buffer A- 
0.05 % FA and buffer B- 0.05% FA with 100% Acetonitrile on a linear 
gradient of 20-40% B. Purified protein peak was checked on ESI-MS for its 
purity and freeze dried. The protein was reconstituted in phosphate buffer 
saline and quantified by absorbance at 280 nm before the assay.  
2.2.7. Cloning, expression and purification of ΔHelix and R&H 
Two truncations of KNP were designed based on the predicted structure of 
KNP. Full length KNP lacking the putative helix segment, ΔHelix (Residues 
1-34) and a fusion of ring and helix, R&H (residues 1-22 with residues 39-60) 
were designed. DNA fragments encoding ΔHelix and R&H were obtained 
using specific primers designed to amplify the required segment out of DNA 
encoding KNP. Strategies of cloning, expression and purification involved 
same procedure as described above. 
2.2.8. Synthesis of ANP, Ring and Helix 
Peptides were synthesized using manual 9-fluorenylmethoxycarbonyl (Fmoc)-
solid phase peptide synthesis. All amino acids used were Fmoc-L-(amino 
acid)-OH derivatives, with some residues containing side-chain protection 
groups. The side-chain protected amino acids used were: Arg(Pbf), Asn(Trt), 
Asp(OtBu), Cys(Trt), Gln(Trt), Glu(OtBu), His(Trt), Ser(tBu), Thr(tBu), and 
Tyr(tBu). 
  ANP was synthesized using Tyr-preloaded Wang resin, Helix using Novasyn 
TGA resin and Ring using Novasyn TGR resin. Synthesis scale was set to 0.2 
mmol and the appropriate quantity of resin was swollen in DMF. After 
washing the resin with DMF, an iterative procedure of coupling-deprotection-
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coupling was carried out from C-terminal residue of the peptide to N-terminus. 
Coupling involved activation of 5 times excess of Fmoc-Amino acid 
derivatives using 4.9 times HATU and 10 times DIPEA in a reaction 
performed in the ratio 2:1 DMF: NMP. Following coupling, resin was washed 
with DMF and deprotection of the F-moc group using 20% (v/v) piperidine in 
DMF was done. 
After the completion of synthesis, the resin was washed thrice with DMF-
DCM-methanol and dried. The peptides were cleaved from the resin using 
TFA:EDT:TIS:water (94:2.5:1:2.5) and precipitated using ice cold 1,2 diethyl 
ether. The crude peptides were purified using Jupiter C18 column (5 µm, 300 
Å  10 X 250 mm) using a linear gradient  with buffer A-0.1 % Trifluroacetic 
acid (TFA) and Buffer B- 0.1% TFA with 80% acetonitrile, on Akta purifier 
system (GE Healthcare). The purity and homogeneity of the peptides were 
assessed using ESI-MS and pure fractions were freeze fried.  
ANP was subjected to air oxidation in 100 mM Tris-HCl pH 8 with 10% 
acetonitrile while Ring was oxidized using 100 mM Tris-HCl pH 8, 20% 
DMSO and 10% Acetonitrile at final peptide concentration of 0.5 mg/ml. The 
oxidized peptides were purified by RP-HPLC and the mass of the peptides 
determined by ESI-MS. 
2.9. Vasorelaxation assay 
Male Sprague Dawley (SD) rats (10 weeks old) were euthanized  and the 
descending thoracic aorta was isolated and flushed with physiological solution 
(Krebs Buffer: 118 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM 
MgSO4, 1.25 mM CaCl2, 25 mM NaHCO3, 11 mM glucose, pH 7.4). The fat 
tissues and connective tissues on aorta were removed, cut into 2-3 mm rings 
 58 
 
and mounted under 2.5 g tension into the organ bath chamber using two 
stainless steel hooks. The aortic strips were fixed to MLT0201/RAD Force 
transducer (AD Instruments). The tissues were equilibrated in chambers at 
37  C containing carbogenated (95% O2 and 5% CO2) Krebs buffer for an hour. 
The presence of endothelium in the aortic strip was checked by pre-
contracting the tissue with 300 nM phenylephrine (PE) and relaxing with 10 
µM Acetylcholine (ACh). The aortic rings were pre-contracted with 100 nM 
PE and a cumulative dose response for different peptides/ protein was 
obtained. Further, the aorta was denuded of endothelium by rubbing the inner 
surface of the aortic ring with a cotton bud and then pre-contracted with 100 
nM PE to construct the cumulative dose-response of the protein/peptides. The 
efficiency of removal was confirmed by no relaxation response to Ach 
treatment. 
 
To study the effect of different inhibitors, the tissue was incubated with 
individual inhibitors including 100 µM L-NAME (L- arginine methyl ester 
hydrochloride, inhibitor of NO synthesis), 10 µM Indomethacin 
(cycloxygenase 1 and 2 inhibitor) or 20 µM ODQ (1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one, soluble guanylyl cyclase inhibitor) for 20 min prior to pre-
contraction of tissue. The inhibition was confirmed by attenuated relaxation on 
Ach treatment. To understand the role of hyperpolarization in mediating KNP 
signalling, tissues were pre-contracted with 40 mM KCl. The pre-contracted 
tissue in the presence of a particular inhibitor was used to assess the activity of 
300 nM of either ANP/KNP. The relaxation response of different peptides was 
assessed on three independent tissues. Data are represented as mean ± SEM. 
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Contraction response of aortic strips with 100 nM PE is considered 0% 
relaxation. Subsequent relaxation of the aortic strips is in response to different 
concentrations of the peptide is represented as percentage relaxation. 
Statistical analysis of the relaxation curves was done using one-way ANOVA 
with one-tail student t-test and significance was accepted for a P-value < 0.05.  
 
2.2.10. Measurement of Mean arterial pressure and urine volume 
Experiments were performed on male Sprague Dawley (SD) rats (220-300 g) 
in accordance with protocol 041/12 approved by the Institutional Animal Care 
& Use Committee (IACUC), NUS. Rats were anesthetized with 60-70 mg/kg 
Pentobarbital (IP) and placed on heating pad at 37°C to maintain body 
temperature. Urinary bladder catheterization was performed as illustrated in 
(Robinson et al., 2012) with certain modifications as described. A midline 
incision was made to expose the urinary bladder. The bladder was retracted 
and an 18 G needle was used to puncture the bladder neck. A 5 cm long PE 50 
catheter was cut at one end to have a pointed and elliptical end, which was 
introduced into the bladder through the puncture. A purse-string suture was 
placed in the bladder surface at the site of entry of the catheter to secure it. 
0.9% saline was injected into the bladder through the catheter to check if the 
bladder was leaking. 
Subsequently, a left oblique groin incision was made to expose the femoral 
artery and vein which were isolated and cannulated. After the surgery 1 ml of 
0.2% BSA containing saline was injected intravenous to compensate for 
surgical loss. A fluid filled physiological pressure transducer (MLT 844, AD 
Instruments) filled with 50 IU/ml heparinized saline was connected to the 
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femoral artery catheter, while saline containing 0.2% BSA was infused 
through the catheter inserted into femoral vein at 2 ml/h for equilibration 
period of 20 min. Mean Arterial Pressure (MAP), heart rate and urine volumes 
were measured continuously. The experiment begun with a control periods (C- 
10 min) followed by 2 experimental periods (E1 and E2, 5 min each) during 
which 0.2 nmol/kg/min ANP or 2 nmol/kg/min KNP or Ring or Helix or 
ΔHelix in 0.2% BSA saline was infused. The animal was left to recover for 40 
min (R1-R4, four recovery periods of 10 min each) during which 0.2% BSA 
saline was infused. Each peptide was assessed for its bioactivity in five 
independent trials and the statistical analysis was performed between different 
time points of ANP and KNP related peptides using one-way student t-test and 
a P-value < 0.05 was considered to be significant. 
2.2.11. Cell culture 
CHO-K1 cells were maintained in high-glucose Dulbeco’s modified eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 
U/ml penicillin and 100 µg/ml streptomycin and 2 mM glutamine in a 
humidified incubator at 37°C with 5% CO2. The cells were sub-cultured by 
trypsinization every three days. The cells were counted using a Bio-rad 
TC20
TM
 automated cell counter. 
2.2.12. NPR-A and NPR-B plasmid preparation 
Plasmids encoding NPR-A and NPR-B were generously gifted by Dr. Ruey-
Bing Yang (Academia Sinica) and Prof. Micheala Kuhn (University of 
Wurzburg). The plasmids were transformed into JM109 as described 
previously. A single colony of the transformant was inoculated in 100 ml of 
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LB broth containing 100 µg/ml ampicillin and was grown at 37°C, 200 rpm 
for 22-24 h. The cells were harvested by spinning at 5,000 g for 20 min and 
the plasmids were extracted using Pure yield
TM
 plasmid maxiprep kit 
(Promega) using manufacturer’s protocol. The DNA concentration was 
evaluated using nanodrop as described previously. 
2.2.13. Transfection of CHO-K1 cells 
1X10
5
 cells were seeded per well in a 24- well plate. The cells were allowed to 
growth for 20-22 h before transfection. The used media was aspirated from the 
wells and replenished with 400 µl of DMEM containing 10% FBS without any 
antibiotics. Each well was provided with 0.8 µg plasmid diluted in 50 µl of 
serum free DMEM media. Two µl of lipofectamine
TM
 2000 was diluted in 50 
µl of serum free DMEM media was added. Diluted DNA and transfection 
reagent were mixed and incubated at room temperature for 10-15 min. The 
DNA- lipofectamine mixture (100 µl/ well) was directly added to the cells 
within 30 min. The cells were incubated with the DNA-lipid complex for 6 h 
at 37°C with 5% CO2.  After 6 h the media containing DNA and lipofectamine 
was aspirated and replaced with DMEM containing 10% FBS and antibiotics. 
These cells were incubated at 37°C with 5% CO2 for 16- 20 h before it is 
treatment with the peptides. 
2.2.14. Whole cell cGMP elevation assay 
CHO-K1 cells transfected with either NPR-A/ NPR-B/ empty-vector 
pCMV4.0 were used. Post transfection, the media was aspirated and the cells 
were washed with 500 µl of PBS. The cells were incubated for 30min after the 
addition of 150 µl of 0.5 mM IBMX containing vascular growth media. 
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Meanwhile peptides were reconstituted in 4X concentrations. After 30 min of 
incubation, 50 µl of peptide solution was added to the cells followed by 
further incubated for 30 min at 37°C with 5% CO2. Subsequently peptide 
containing basal media was removed and 150 µl of 0.1 M HCl was added and 
incubated at room temperature for 30 min with shaking at 50 rpm. The cell 
lysates were collected and assayed for cGMP levels using Enzo life sciences 
cGMP ELISA kit, as per the manufacturer’s protocol. Total protein content of 
the cell lysates of a few wells was determined by BCA (bichinchonic acid) 
assay and this value was used to normalize across different 24 well plates 
used. Three independent trials for each peptide was done and the statistical 
comparison between ANP or CNP and KNP related peptides was performed 
using one-tail ANOVA with t-test and curves with a P-value <0.05 was 





2.3.1 Sequence and structural analysis of KNP 
The transcriptome of B. flaviceps revealed the transcript which encodes 148-
residue precursor protein (Figure 2.1). B. flaviceps is an uncommon snake 
which is hard to obtain and difficult to keep in captivity. Further, venom yields 
per milking are low. Therefore, we were unable to identify the size of the 
mature KNP protein in the venom. There are three dibasic processing sites in 
the precursor protein. Processing at the second dibasic site at position 87 leads 
to 5-residue N-terminal segment ahead of the conserved 17-membered NP 
ring; such short N-terminal extensions are found in all known NPs (Figure 
1.8). Processing at the third dibasic site at position 113 leads to two-residue C-
terminal tail; such short tails have not found in elapid NPs and hence, we 
assumed that the processing may not occur at this site. Therefore, we 
hypothesized that mature KNP is 60-residue long with a 38-residue tail. The 
C-terminal tail did not show similarity to any protein in the database and 
interestingly, the last 21 residues showed propensity to form α- helix (Figure 
2.1). Despite the presumption, we also tested the functions of the shorter 
version of KNP with a short two-residue tail (see below). Because of the 
unique structural features, we were interested in understanding the functional 






Figure 2.1.  Sequence and structural analysis of KNP  
Precursor KNP was identified from the transcriptome of the venom gland of 
Bungarus flaviceps. It encoded a 148-residues protein along with a signal peptide 
(sequence represented in bold). The possible maturation sites in the proteins are 
dibasic residues (indicated in red bold letters). The mature protein was assumed to be 
60 residues protein with both Cys residues in a disulphide bond. The secondary 
structure prediction using PSI-PRED, showed that the last 21 amino acid residues of 
KNP tail had propensity to form an α-helix. 
 
 
2.3.2 Heterologous expression and purification of KNP 
As there was no natural venom source, we recombinantly expressed and 
purified KNP. Mature protein was heterologously expressed in E. coli as Trx-
His-fusion protein (Figure 2.2). This protein was obtained from the insoluble 
fraction. Following a 2 M urea wash, the protein pellet was solubilized protein 










performance liquid chromatography (RP-HPLC), and the purity of the protein 
was assessed using ESI-ion trap mass spectrometry. Fusion protein showed 
23734.9 ± 1.9 Da which matched with the calculated mass. The fusion protein 
was cut by recombinant TEV protease and purified by cation exchange 
chromatography (CIEX) followed by RP-HPLC. The protein peak showed 
mass of 6602.3 ± 0.9 Da which corresponded to the calculated mass of the 
oxidized KNP. Thus completely oxidized KNP was obtained and was used to 
assess its function. 
2.3.3 Purification of ANP 
ANP was synthesized by manual Fmoc-based peptide synthesis. The cleaved 
and purified peptide showed mass of 3082.0 ± 0.5 Da which was 
corresponding reduced mass of the peptide. It was folded by air-oxidation and 
the peptide after folding showed mass of 3080.6 ± 0.5 Da indicating the 




Figure 2.2.  Heterologous expression and purification of KNP 
A: A 15 % SDS-PAGE analysis shows the expression of trx-KNP fusion protein in 
insoluble fraction.  M- Precision Plus protein
TM
 Dual color standard,  UI- Uninduced 
E. coli whole cell lysate, I- Induced E. coli whole cell lysate,  S- Supernatant 
containing soluble protein after cell lysis, P- Pellet containing insoluble proteins. B: 
The trx-fusion protein was purified by reversed-phase high performance liquid 
chromatography using 0.05% formic acid (FA) as buffer-A and 100% Acn with 
0.05% FA as buffer-B. The separation was performed on Jupiter C18 column (5µm, 
300 Å 250 X 21.2 mm) with a linear gradient of 40- 70% B. The arrow indicates the 
protein of interest. C: Mass of the protein peak indicated by the arrow in panel B was 
determined by ESI Ion-Trap mass spectrometry. Peaks obtained were reconstructed to 
obtain a mass of 23734.9 ± 1.9 Da which corresponded to the mass of trx-KNP fusion 
protein. Pure fractions of the protein were freeze dried. D: The freeze dried fusion 
protein was dissolved in 50 mM Tris-HCl, 6 M urea pH 8 buffer. This protein was 
desalted with 50 mM Tris-HCl pH 8. TEV protease cleavage reaction was set with 
protein obtained at a ratio 1:40 (TEV: protein) at 4°C for 16-20 h. Cleaved protein, 
tag and uncut fusion  protein were separated using cation exchange  chromatography 
using 50 mM Tris-HCl pH 8 as buffer-A and 50 mM Tris-HCl, 500 mM NaCl pH 8 
as buffer-B. The chromatographic separation was performed using Hi-Trap-
Sulfopropyl (SP)-Sepharose column (34 μm, 16 X 25 mm) with a linear gradient of 0-
100% B.  The arrow indicates the protein peak which was subsequently purified. E: 
Peak indicated in panel D was run on RP-HPLC using Jupiter C18 column (5 µm, 
300 Å ,250 X 10 mm) with 0.05% FA as buffer-A and 100% Acn with 0.05% FA as 
buffer-B on a linear gradient of 15- 50% B. Arrow indicates is the protein of interest. 
F: Mass of the protein indicated from panel E was determined by ESI-ion trap mass 
spectrometer. The reconstructed mass of the mass spectrum indicated a protein of 

















































































































































































































































































Figure 2.3.  Purification of ANP 
A- ANP was synthesized by F-moc based manual SPPS and purified by RP-HPLC. 
Crude mixture of reduced peptides were separated on Jupiter C18column (5µm, 300 
Å, 250 X 21.2 mm) using 0.1% TFA as buffer A and 0.1% TFA with 80% Acn as 
buffer B. A linear gradient 20- 30% B was used to obtain the purified peptide. Arrow 
indicates the peptide peak of interest. B- Mass of the peptide indicated in panel A was 
determined by ESI-ion trap mass spectrometer. The reconstructed mass spectrum 
indicated a protein of mass 3082.0 ± 0.5 Da, which corresponded to reduced mass of 
ANP. C- Purified ANP was folded in 100 mM Tris-HCl pH8 containing 10% Acn for 
24 h. This folding mixture was purified by RP-HPLC using Jupiter C18 column 
(5µm, 300 Å, 250 X21.2 mm) using a linear gradient of 20- 30% B (0.1% TFA as 
buffer A and 0.1% TFA with 80% Acn as buffer B). Arrow indicates the peptide peak 
of interest. D- Mass of the peptide indicated in panel C was determined by ESI-ion 
trap mass spectrometer. The reconstructed mass spectrum indicated a protein of mass 
3080.6 ± 0.4 Da, which was 2 Da lesser than the mass of ANP before folding, 

































































































































3080.55 ± 0.4 Da






2.3.4 Ability of KNP and ANP to relax pre-contracted aortic strip 
ANP and KNP induced vasorelaxation in the pre-contracted rat aortic strips 
(Figure 2.4). ANP induced a dose-dependent vasorelaxation with an EC50 of 
16.3 ± 5.4 nM was comparable to EC50 values reported in the literature (Fiscus 
et al., 1985). KNP also induced a dose-dependent vasorelaxation, but with 
~13-fold lower potency (EC50 230.6 ± 37.2 nM) (Figure 2.4 B).  ANP caused a 
quick vasodilatory response at ≥ 10 nM, while KNP induced slow relaxation 
for all the concentrations tested (Figure 2.4 A). We also examined the effects 
of KNP on vasorelaxation in endothelium-denuded aortic strips. ANP induced 
equipotent vasorelaxation with an EC50 of 23.4 ± 7.8 nM, as NPRs are 
expressed in both endothelium as well as vascular smooth muscle (Lowe et al., 
1989). Interestingly, the activity of KNP was significantly (P-value: 0.0043) 
reduced when endothelium was denuded (Figure 2.4 C). Thus, KNP mediates 
endothelium-dependent vasodilatory response, which is not NPR NPR-





Figure 2.4.  KNP mediates endothelium dependent vasorelaxation 
A- Data Acquisition of aortic strip relaxation- Thoracic aorta was isolated from 10 
weeks old SD rats and cut into 2-3 mm rings which were mounted at 2 g tension 
resting tension in an organ bath. The tissue was equilibrated for an hour following 
which the viability of the tissue was assessed by pre-contracting it with 300 nM PE 
and  relaxation in response to 10 µM Ach was indicative of presence of endothelium. 
The tissue was washed and allowed to rest before pre-contracting it again with 100 
nM PE. A cumulative dose response of ANP (left) and KNP (right) are shown as a 
representation. Each peptide was tested on three independent aortic strips. B- 
Cumulative dose response of ANP and KNP on pre-contracted aortic strip with intact 
endothelium: Aortic rings were pre-contracted with 100 nM PE. After the 
stabilization of response to PE, cumulative dose response is assessed. The tissue is 
incubated with each concentration for 10 min before the additive dosage was given. 
The data are represented as mean ± SEM and the P-value is 0.005.C- Cumulative 
dose response of ANP and KNP in pre-contracted aortic strip with denuded 
endothelium: The inner lining of the aortic strip was rubbed with cotton bud to 
remove endothelium. The absence of endothelium was check with the response to 10 
µM Ach after the pre-contraction with 300 nM PE. Tissues which showed no 
response to Ach were used to assess the dose response. Data represented as mean ± 
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2.3.5 Effect of KNP and ANP on mean arterial pressure (MAP), pulse 
pressure (PP), heart rate and urine output 
We examined the effects of KNP on blood pressure, heart rate and urine 
output in experimental animals (Figure 2.5). ANP and KNP were 
intravenously infused into two groups of anesthetized rats for 10 min. The 
baseline MAP of the animals used were 114.5 ± 2.4 mmHg. In comparison to 
control animals (0.2% BSA saline infused n = 5) infusion of ANP (0.2 
nmol/kg/min in 0.2% BSA saline n = 5) induced 6.5 ± 0.9 mmHg drop in 
MAP at the end of the infusion period which dropped reaching 8.5 ± 0.5 
mmHg during the first 10 min recovery. By the end of 30 min the MAP was 
restored to the baseline. A 10-fold higher dosage was chosen for KNP based 
on the difference in activity on the aortic strip. KNP (2 nmol/kg/min in 0.2% 
BSA saline n = 5) showed a similar reduction in MAP at the end of the 
infusion period (6.1 ± 3 mmHg) (Figure 2.6 A). MAP continued to drop 
further reaching a difference of 11.9 ± 1.9 mmHg after the second recovery 
period. Although the MAP of animals infused with KNP started recovering, it 
did not recover back to the baseline within the experimental recovery period 
(40 min); at the end of 40 min, MAP was 10 ± 3 mmHg below the baseline 
(Figure 2.6 A). Thus, KNP induced a sustained drop in MAP compared to 
ANP.  
ANP caused a steep drop in pulse pressure (PP), calculated as the difference of 
systolic BP and diastolic BP (Baseline PP: 47.4 ± 2.4 mmHg), by 7.2 ± 0.9 
mmHg during infusion. PP began to restore back to baseline by the end of the 
experiment (Figure 2.6 B). In the case of KNP, although there was a milder 
drop in PP (3.7 ± 1 mmHg), it did not restore back during recovery period. PP 
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is dependent on stroke volume and compliance of arteries. ANP is shown to 
reduce venous return of blood to the heart, which decreases stroke volume 
(Sasaki et al., 1985). In the case of KNP, change in systolic BP was 
comparable to ANP, while decrease in diastolic BP was more profound (ANP: 
6.5 ± 1 mm Hg, KNP: 11.1 ± 1.8 mmHg). Due to similar differences in 
systolic and diastolic BP, the net PP was not greatly altered for KNP (Figure 
2.7).  
Baseline heart rates of the animals were 371.9 ± 10.9 BPM. When ANP was 
infused, the heart rate was reduced by 39.9 ± 23.6 BPM during infusion which 
further dropped to a difference of 58.1 ± 19 BPM within the first recovery 
period (Figure 2.6 C)(Kubo et al., 1990; Shapiro et al., 1986). The reduced 
heart rate recovered back to baseline within the next 30 min. In the case of 
animals infused with KNP, the reduction in heart rate was not as profound 
(10.6 ± 21 BPM). But during the recovery period, heart rate persistently 
dropped reaching a difference of 42.1 ± 16 BPM at the end of experimental 
period (Figure 2.6 C). 
In the same experimental animals, urine was collected throughout the 
experimental period by bladder catheterization. The baseline urine flow rate 
was 3.7 ± 0.5 µl/min. ANP showed marked diuresis with an increased flow 
rate of 8.8 ± 1.4 µl/min. The urine flow rate returned back to baseline within 
20 min of recovery. Similar changes in renal output were observed previously 
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Figure 2.5.  Data acquisition for blood pressure measurement 
Femoral vein and artery, urinary blabber catheterization was performed for rats anesthetized with sodium pentobarbital. A fluid- filled 
pressure transducer was inserted into femoral artery and infusion saline/ peptide was given through a syringe pump at a constant flow rate of 
2 ml/h through femoral vein. Urine was collected over a period of 10 min. After the completion of surgery the animals were equilibrated for 
20 min and the end of which the time is assumed to be t = 0. Following a control period of 10 min, ANP (0.2 nmol/kg/min) or KNP (2 
nmol/kg/min) was infused for 10 min. Subsequently, the animals were let to recover for 40 min. During control and recovery periods, 0.2% 
BSA saline was infused. Blood pressure/ heart rate/ urine flow rate value at t = 0 was assumed as baseline. Average values over a time period 
of 10 min is used for calculation. (ANP: n = 5, KNP: n = 5) 
 73 
 
                                      
Figure 2.6.  KNP causes a prolonged reduction in MAP, PP and heart rate with no renal effects 
A: Mean arterial pressure (MAP) was calculated as (⅓ systolic pressure + ⅔ diastolic pressure). Change in MAP with reference to the 
baseline was plotted against time. B: Pulse pressure (PP) was calculated as difference between systolic and diastolic pressure. Change in PP 
with reference to the baseline was plotted against time. C: Heart rate (HR) was calculated as number of beats per minute. Change in HR with 
reference to baseline was plotted against time. D: Urine output was represented as volume of urine collected per minute. Change in urine flow 
rate with reference to the baseline was plotted against time. Each group of peptide and control were tested on five independent animals and 
the data are represented as mean ± SEM. Statistical analysis between ANP and KNP were performed using one way student t-test and the data 
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(Frolov et al., 1989). In contrast, the infusion of KNP showed only a minor 
increase in urine flow rate (2 ± 1.2 μl/min) which was sustained all throughout 
the experimental period (Figure 2.6 D). 
These results indicate that KNP influences blood pressure, heart rate and renal 
output differently than ANP and further supports on contention that KNP 
exerts its biological effects through a distinct mechanism. 
 
          
Figure 2.7.  KNP causes a profound change in diastolic pressure 
Change in systolic, diastolic and PP with reference to baseline was plotted against 
time for animals infused with A- ANP (n = 5) and B- KNP (n = 5). Data are 




















































2.3.6. Design and Synthesis of KNP mutants 
To understand the structure-function relationships and the role of distinct 
regions in KNP, we designed several truncated and deletion mutants (Figure 
2.8). We designed two fragments of KNP, C-terminal α-helix (Helix, residues 
35-60) and the entire KNP without this α-helix (ΔHelix, residues 1-34). We 
also designed a conserved 17-membered ring with two C-terminal residues 
(Ring, residues 1-24) to help understand the bioactivity of the NP ring and a 
fusion of the ring with helix (R&H fusion of residues1-22 with residues 39-
60). Ring and Helix were manually synthesized by SPPS, while ΔHelix and 
R&H were cloned from the full length KNP and heterologously expressed and 
purified. The masses of Ring, Helix, ΔHelix and R&H peptides assessed using 
ESI–MS matched the theoretical masses (Table 2.1).  
Table 2.1. List of observed and theoretical mass of KNP deletion mutants 
 
Oxidized mass of the peptides are indicated by *
Construct Observed mass (Da) Theoretical mass (Da) 
KNP 6602.3 ± 0.9 6602.5* 
ANP 3080.6 ± 0.4 3080.2* 
Ring 2768.7 ± 0.7 2769.1* 
Helix 2765.1 ± 1.0 2765.7 
ΔHelix 3855.6 ± 1.2 3855.8* 
R&H 5052.5 ± 0.6 5052.4*  
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Figure 2.8.  Schematic representations of KNP and its deletion mutants 
The deletion mutants of KNP were designed based on the predicted structure and the processing sites of KNP. 
Δ Helix: Last 26 residues of KNP which had the putative helical segment was deleted to mimic other known elapid NPs 
Helix: Last 26 residues of the C-terminal tail of KNP  
Ring: Ring of KNP with 2 residue tail was designed to mimic mammalian NPs  






























































































































































Figure 2.9.  Heterologous expression and purification of ΔHelix 
A: A 15 % SDS-PAGE analysis shows the expression of trx-ΔHelix fusion protein in 
insoluble fraction.  M- Precision Plus protein
TM
 Dual color standard,  UI- Uninduced 
E. coli whole cell lysate, I- Induced E. coli whole cell lysate,  S- Supernatant 
containing soluble protein after cell lysis, P- Pellet containing insoluble proteins. B: 
The trx-fusion protein was purified by reversed-phase high performance liquid 
chromatography using 0.05% formic acid (FA) as buffer-A and 100% Acn with 
0.05% FA as buffer-B. The separation was performed on Jupiter C18 column (5µm, 
300 Å 250 X 21.2 mm) with a linear gradient of 40- 70% B. The arrow indicates the 
protein of interest. C: Mass of the protein peak indicated by the arrow in panel B was 
determined by ESI Ion-Trap mass spectrometry. Peaks obtained were reconstructed to 
obtain a mass of 20985.51 ± 0.8 Da which corresponded to the mass of trx- ΔHelix 
fusion protein. Pure fractions of the protein were freeze dried. D: The freeze dried 
fusion protein was dissolved in 50 mM Tris-HCl, 6 M urea pH 8 buffer. This protein 
was desalted with 50 mM Tris-HCl pH 8. TEV protease cleavage reaction was set 
with protein obtained at a ratio 1:40 (TEV: protein) at 4°C for 16-20 h. Cleaved 
protein, tag and uncut fusion  protein were separated using cation exchange  
chromatography using 50 mM Tris-HCl pH 8 as buffer-A and 50 mM Tris-HCl, 500 
mM NaCl pH 8 as buffer-B. The chromatographic separation was performed using 
Hi-Trap-Sulfopropyl (SP)-Sepharose column (34 μm, 16 X 25 mm) with a linear 
gradient of 0-100% B.  The arrow indicates the protein peak which was subsequently 
purified. E: Peak indicated in panel D was run on RP-HPLC using Jupiter C18 
column (5 µm, 300 Å ,250 X 10 mm) with 0.05% FA as buffer-A and 100% Acn with 
0.05% FA as buffer-B on a linear gradient of 15- 50% B. Arrow indicates is the 
protein of interest. F: Mass of the protein indicated from panel E was determined by 
ESI-ion trap mass spectrometer. The reconstructed mass of the mass spectrum 
indicated a protein of mass 3855.6 ± 1.2 Da, which corresponded to the calculated 


























































































































































































































































Figure 2.10.  Heterologous expression and purification of R&H 
A: A 15 % SDS-PAGE analysis shows the expression of trx-R&H fusion protein in 
insoluble fraction.  M- Precision Plus protein
TM
 Dual color standard,  UI- Uninduced 
E. coli whole cell lysate, I- Induced E. coli whole cell lysate,  S- Supernatant 
containing soluble protein after cell lysis, P- Pellet containing insoluble proteins. B: 
The trx-fusion protein was purified by reversed-phase high performance liquid 
chromatography using 0.05% formic acid (FA) as buffer-A and 100% Acn with 
0.05% FA as buffer-B. The separation was performed on Jupiter C18 column (5µm, 
300 Å 250 X 21.2 mm) with a linear gradient of 40- 70% B. The arrow indicates the 
protein of interest. C: Mass of the protein peak indicated by the arrow in panel B was 
determined by ESI Ion-Trap mass spectrometry. Peaks obtained were reconstructed to 
obtain a mass of 22187.7 ± 0.9 Da which corresponded to the mass of trx-R&H 
fusion protein. Pure fractions of the protein were freeze dried. D: The freeze dried 
fusion protein was dissolved in 50 mM Tris-HCl, 6 M urea pH 8 buffer. This protein 
was desalted with 50 mM Tris-HCl pH 8. TEV protease cleavage reaction was set 
with protein obtained at a ratio 1:40 (TEV: protein) at 4°C for 16-20 h. Cleaved 
protein, tag and uncut fusion  protein were separated using cation exchange  
chromatography using 50 mM Tris-HCl pH 8 as buffer-A and 50 mM Tris-HCl, 500 
mM NaCl pH 8 as buffer-B. The chromatographic separation was performed using 
Hi-Trap-Sulfopropyl (SP)-Sepharose column (34 μm, 16 X 25 mm) with a linear 
gradient of 0-100% B.  The arrow indicates the protein peak which was subsequently 
purified. E: Peak indicated in panel D was run on RP-HPLC using Jupiter C18 
column (5 µm, 300 Å ,250 X 10 mm) with 0.05% FA as buffer-A and 100% Acn with 
0.05% FA as buffer-B on a linear gradient of 15- 50% B. Arrow indicates is the 
protein of interest. F: Mass of the protein indicated from panel E was determined by 
ESI-ion trap mass spectrometer. The reconstructed mass of the mass spectrum 
indicated a protein of mass 5052.9 ± 0.6 Da, which corresponded to the calculated 
























































































































































































































































22187.71 ± 0.9 Da 5052.9 ± 0.6 Da
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Figure 2.11.  Purification and oxidation of Ring 
A- Ring was synthesized by F-moc based manual SPPS and purified by RP-HPLC. 
Crude mixture of reduced peptides were separated on Jupiter C18column (5µm, 300 
Å, 250 X 21.2 mm) using 0.1% TFA as buffer A and 0.1% TFA with 80% Acn as 
buffer B. A linear gradient 20- 30% B was used to obtain the purified peptide. Arrow 
indicates the peptide peak of interest. B- Mass of the peptide indicated in panel A was 
determined by ESI-ion trap mass spectrometer. The reconstructed mass spectrum 
indicated a protein of mass 2770.1 ± 0.5 Da, which corresponded to reduced mass of 
Ring. C- Purified Ring was folded in 100 mM Tris-HCl pH8 containing 10% Acn for 
24 h. This folding mixture was purified by RP-HPLC using Jupiter C18 column 
(5µm, 300 Å, 250 X21.2 mm) using a linear gradient of 20- 30% B (0.1% TFA as 
buffer A and 0.1% TFA with 80% Acn as buffer B). Arrow indicates the peptide peak 
of interest. D- Mass of the peptide indicated in panel C was determined by ESI-ion 
trap mass spectrometer. The reconstructed mass spectrum indicated a protein of mass 
2768.2 ± 0.7 Da, which was 2 Da lesser than the mass of Ring before folding, 
suggesting the formation of disulphide linkage 
 
      
Figure 2.12.  Purification of Helix 
A- Helix was synthesized by F-moc based manual SPPS and purified by RP-HPLC. 
Crude mixture of peptides were separated on Jupiter C18 column (5µm, 300 Å, 250 X 
10 mm) using 0.1% TFA as buffer A and 0.1% TFA with 80% Acn as buffer B. A 
linear gradient 20- 40% B was used to obtain the purified peptide. Arrow indicates 
the position of elution of Helix. B- Mass of the protein indicated in panel A was 
determined by ESI-ion trap mass spectrometer. The reconstructed indicated a protein 









































































































































2770.1 ± 0.5 Da









































































2765.2 ± 0.5 Da
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2.3.7. Vasodilatory properties of KNP deletion mutants 
The truncated segments of KNP were assessed for their ability to relax pre-
contracted aortic strip (Figure 2.13). The EC50 values of the different mutants 
are listed in table 2.2. The Ring evoked equipotent relaxation in aortic strips 
with and without endothelium (P-value: 0.33 no significant difference). 
Although Ring’s ability to relax was equivalent to full length KNP (P-value: 
0.25 no significant difference), it elicited an endothelium independent 
relaxation similar to a classical NP. 
Table 2.2. EC50 of ANP, KNP and KNP mutants for inducing 
vasorelaxation 
Construct EC50 (nM) ± SEM 
Endothelium + Endothelium - 
ANP 16.3 ± 5.4 23.4 ± 7.8 
KNP 230.6 ± 37.2 - 
Ring 228.6 ± 43.1 279.5 ± 47.2 
Helix 326.7 ± 64.3 - 
R&H 267.13 ± 45.7 - 
ΔHelix > 1000 > 1000 
 
ΔHelix with the putative helical segment deleted had much lowered potency to 
induce relaxation compared to KNP (P-value: 0.0002), but it showed 
equivalent response in both the population of aortic strips. Helix and R&H 
showed vasorelaxation ability in strips with endothelium with equivalent 
potency as KNP (P-value: 0.25) which was significantly reduced on removing 
endothelium (P-value of helix with and without endothelium: 0.015, P-value 
R&H of with and without endothelium: 0.02). These results suggest that C-
terminal putative helix forming region of KNP contributes to its entire activity, 




Figure 2.13. Helix mediates the vasodilatory effects of KNP 
A- Cumulative dose response of KNP deletion mutants in endothelium intact aortic strips- Aortic strip was pre-contracted with 100 nM PE 
and the dose response of different peptides have been evaluated. B- Cumulative dose response of KNP deletion mutants in endothelium 
denuded aortic strips- strip was pre-contracted with 100 nM PE and the dose response of different peptides have been evaluated. 
Every data point is an average of three independent trials for each concentration of the peptide and is represented as mean ± SEM. Statistical 














































to redirect the ring of KNP away from NPR, which is evidently shown by the 
modulated activity of KNP and R&H in the presence and absence of 
endothelium. 
2.3.8. Activation of NPR-A and NPR-B by KNP and its mutants 
To understand the ability of the KNP and its mutants to activate NPR-A and 
NPR-B, cells endogenous lacking these receptors (CHO-K1) were transfected 
with plasmids encoding rat NPR-A and NPR-B separately. The abilities of 
KNP and its deletion mutants to induce signal transduction and evoke cGMP 
response in these cells were measured and compared with those of ANP on 
NPR-A and CNP on NPR-B.  
On cells expressing NPR-A, ANP evoked a dose-dependent cGMP response 
(Figure 2.14 A). Ring elicited a 10-fold less potency compared to ANP. 
Interestingly, C-terminal extensions in KNP, ΔHelix and R&H led to further 
loss in cGMP response. Helix did not cause any elevation of cGMP indicating 
that it does not interact with NPR-A. These observations were in agreement to 
the vasodilatory properties of these peptides. 
On cells expressing NPR-B, CNP evoked highly potent cGMP response. 
However, as expected because of the presence of C-terminal residues, KNP 
and its deletion mutants were not able to evoke any cGMP response in cells 
expressing NPR-B (Figure 2.14 B).  
These results show that Ring is a specific ligand to NPR-A, but with a lower 
potency compared to ANP and the presence of the C-terminal tail redirects the 




Figure 2.14.  C-terminal tail of KNP redirects the ring away from NPR 
A- Dose dependent cGMP response of ANP, Ring, KNP, Δ Helix, R&H, Helix were evaluated on CHO-K1 cells transfected with plasmid 
encoding NPR-A. B- Dose dependent cGMP response of CNP, Ring, KNP, Δ Helix, R&H, Helix were evaluated on CHO-K1 cells 
transfected with plasmid encoding NPR-B. Data points of 3 independent trials have been plotted as mean ±SEM. Statistically analysis has 
been performed using one-way ANOVA using one way t-test for comparing the different dose response curves with ANP or CNP. * 














































































2.3.9. Downstream activators of KNP signaling 
As KNP and Helix require endothelium to function, we examined the role of 
various intermediates involved in endothelium-mediated vasorelaxation. 
Endothelial cells respond to different vasoactive factors by synthesizing nitric 
oxide (NO), prostacyclins and factor that stimulate hyperpolarization of 
smooth muscle (Mitchell et al., 2008) (Figure 2.15 A). These factors diffuse 
from endothelium to the vascular smooth muscle to arouse cGMP/cAMP 
levels to mediate vasorelaxation (Ignarro, 1989). In a NPR mediated signaling, 
the cGMP is aroused by the GC domain linked to the receptor. Hence, the 
above mentioned vasoactive factors have negligible role in NP-NPR-signaling. 
Therefore, we used specific inhibitors namely L-NAME for Nitric oxide 
synthase (NOS), indomethacin for cycloxgenase 1 and 2 (COX), ODQ for 
soluble guanylyl cyclase (sGC) and KCl-induced pre-contraction to subdue the 
hyperpolarization process (Figure 2.15 A), to investigate the role of the 
endothelium-derived vasoactive factors in KNP signaling.  
ANP’s ability to relax the pre-contracted aortic strip was unmodulated in the 
presence of any of the inhibitors (Figure 2.15 B). With KCl-pre-contracted 
strips there was a slight decrease in the activity. Similar to ANP, Ring also had 
no influence of L-NAME, ODQ and indomethacin on its activity, but lost 
about 30% of its activity which pre-contracted with KCl. Thus, Ring acts 
similar to classical NPs and does not require any endothelial factors to cause 
vasodilation. A NPR-mediated vasodilation involves cGMP-dependent 
activation PKG which phosphorylates (a) myosin light chain and  (b) opens 
big conductance potassium channel leading to hyperpolarization (Alioua et al., 
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1998). These two processes cause the smooth muscle relaxation. Thus, the 
activity of ANP and Ring are lowered when KCl was used for pre-contraction. 
 
KNP’s activity was completely abrogated in the presence of L-NAME. NO 
either activates COX or diffuses to vascular smooth muscle and activates 
soluble guanylyl cyclase (sGC) (Stankevicius et al., 2003) (Figure 2.15 A). 
The inhibition of COX-1 and COX-2 by indomethacin and that of sGC by 
ODQ leads to 60% and 90% loss of KNP’s activity, respectively. Similarly, 
inhibition by L-NAME and ODQ completely abolished the ability of Helix to 
cause vasodilation, while COX inhibition by indomethacin resulted in 70% 
reduction in its activity. These results indicate that NO plays a key role in 
KNP-induced vasorelaxation. KNP evoked 25% relaxation in KCl-contracted 
aortic strips; this is 50% lower when compared to PE-contracted strips. Helix 
failed to evoke relaxation of KCl-contracted aortic strip. These results can be 
explained in two alternate ways: (a) hyperpolarization plays an important role 
in KNP signaling, but not in Helix signaling; and (b) high salt concentration 
breaks the interaction of Helix with its receptor. The second possibility is 
supported by high density of positively (4) and negatively (2) residues in 26 
residues. In this scenario, high salt would also interfere with binding of C-
terminal helix to its receptor and the observed partial activity could be due to 
the binding of the KNP ring. However, further studies are required to clarify 
the role of hyperpolarization.  
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Figure 2.15.  KNP requires NO, prostacyclin and hyperpolarization factor 
for vasodilation 
A- Schematic representation of endothelium dependent vasorelaxation pathway 
In response to agonist s such as Acetylchloline/ Bradykinin, receptor mediated activation of 
Phospholipase C produces IP3 and DAG as secondary messengers. IP3 causes the intracellular 
Ca
2+







 channels to cause hyperpolarization.  
Activation of  NOS, stimulates production of nitric oxide (NO).Subsequently, NO binds to 
heme-core of cycloxygenase (COX) and diffuses to smooth muscle to activate soluble 
guanylyl cyclase (sGC) thereby increasing cGMP. COX produces prostacyclins, which 
diffuses to smooth muscle to elevate cAMP levels. K+ ions from the endothelium cells open 
the K+ channels of smooth muscle, thus causing hyperpolarization. NO, Prostacyclin and 
Hyperpolarization factors are common intermediates identified in endothelium dependent 
vasodilation (Sautebin et al., 1995), (Busse et al., 2002) B- Role of nitric oxide, prostacyclin 
and hyperpolarization factor  in mediating KNP mediated vasorelaxation. The indicated 
inhibitors (L-NAME: 100 µM, Indomethacin: 10 µM, ODQ: 20 µM) were incubated with 
aortic strip for 20 min prior to pre-contraction. Subsequently, the tissue was pre-contracted 
with 100 nM PE and the response of 300 nM of the peptides was tested. KCl (40 mM) was 
used for pre-contraction of the tissue and the response for 300 nM of ANP/KNP/ Ring/ Helix 
was recorded. Each data point is an average of three independent trials and is represented as 
mean ± SEM. The statistical analysis using one-tail student t-test has been performed to 
compare the significance of the response between control aortic strips and inhibitor treated 























































 2.3.10. In-vivo effect of KNP truncations on MAP, PP, heart rate and 
urine output 
To understand the contribution of different pharmacophores of KNP to its in-
vivo activity, Ring, ΔHelix and Helix (2 nmol/kg/min) were intravenous 
infused in experimental rats. Ring decreased MAP  by 10.7 ± 2.5 mmHg 
during infusion which recovered back within the experimental period while 
ΔHelix and Helix caused a mild drop (4.3 ± 1.4 mmHg and 4.7 ± 1.1 mmHg ) 
during infusion period which was sustained during the recovery period (Figure 
2.16 A). Alteration in MAP profile of Ring was similar to that of ANP (P-
value > 0.05; no significant difference) while the additive effect of Helix and 
ΔHelix seemed to reflect KNP’s profile. 
 Ring and ΔHelix caused a meek reduction in heart rate (22.2 ± 12 BPM)  
which quickly returned back to baseline in case of ring while was sustained  in 
case of ΔHelix (Figure 2.16 B). Heart rate remained unperturbed in animals 
infused with Helix similar to control. Although Ring and ΔHelix had lowered 
potencies, the overall heart rate profile of Ring matched that of ANP while 
ΔHelix was similar to KNP. 
 Ring reduced PP to similar extent as that of KNP (4.5 ± 1 mmHg) but 
restored within 20 min after the infusion was stopped (Figure 2.16 C). ΔHelix 
and Helix showed a mild decrease (2 ± 1.3 mmHg) which restored back in 
case of ΔHelix while sustained in case of Helix. Like the heart rate profile, 
Ring evoked similar changes in PP like ANP with lesser effects (at t =30, 40, 
50 and 60 min, P-value < 0.05 compared to ANP) while Helix caused 
comparable effects to that of KNP (P-value > 0.05, no significant difference). 
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None of the KNP truncation had influence on urine volume like the full length 
molecule (Figure 2.16 D). Thus, the overall effect on hemodynamic 
parameters evoked by the Ring was like a classical NP while both the 





                                         
Figure 2.16.  Ring reduces MAP, PP and heart rate like ANP with no renal effects while ring and helix contribute to 
KNP’s function 
A: Mean arterial pressure (MAP) was calculated as (⅓ systolic pressure + ⅔ diastolic pressure). Change in MAP with reference to baseline was plotted 
against time. B: Pulse pressure (PP) was calculated as difference between systolic and diastolic pressure. Change in PP with reference to baseline was 
plotted against time. C: Heart rate (HR) was calculated as number of beats per minute. Change in HR with reference to baseline was plotted against time. D: 
Urine output was represented as volume of urine collected per minute. Change in urine flow rate is plotted against time. Every data point is an average of 
five independent trials and represented as mean ± SEM. The statistically analysis for the comparison of ANP with the different KNP truncations was 

















































































































Figure 2.17.  Changes in systolic and diastolic pressure induced by KNP 
truncations 
Change in systolic, diastolic and PP with reference to baseline was plotted against 
time for animals infused with A- ANP, B- Helix, C- KNP, D- ΔHelix and E- Ring. 




Natriuretic peptides are present in venom. Like mammalian NPs, venom NPs 
are synthesized as precursors and processed to their active form. These mature 
counterparts have the conserved 17-residue ring with variable C-terminal 
extensions. Despite their overall structural similarity, NPs from reptilian 
venom have distinct biological activity compared to mammalian NPs (Section 
1.9). Though this has been attributed to subtle changes in the sequence, no 




































































































This study focuses on the mode of action and structure-activity of KNP, a 
novel NP from Bungarus flaviceps (Siang et al., 2010). The precursor 
encoding KNP was found from the transcriptome analysis of venom gland of 
B.flaviceps, which encoded for a 147 amino acid residues long precursor with 
a signal peptide. The precursor was speculated to be processed at position 87 
after  dibasic (KK) residue by a common prehormone processing enzyme 
Kexin (Rockwell et al., 2002), to produce the mature KNP (60 amino acid 
residues).  Mature KNP has 5 residues in the N-terminal segment, 17-residue 
ring and 38 residues long C- terminal tail. This tail has no similarity to any 
sequence known and is predicted to have the ability to have an α-helical 
structure, which is not reported for any other NP. Ring of KNP has all the 
evolutionarily conserved residues except D residues at position 8 and 19, 
which are G residues in all known NPs. In ANP, F8 and R14 within the ring, 
N24 and R27 in the tail, are pivotal for receptor binding. KNP has F7, R13 and 
R26 in equivalent positions (Bovy, 1990; He et al., 2001; Li et al., 1995). 
Hence, with these structural features one may speculate, KNP with a long C-
terminal tail might interact with NPR-A with lower affinity due to the steric 
hindrance that the tail might impose. 
In contrast to the assumption, KNP evoked aortic strip relaxation in an 
endothelium dependent manner or otherwise NPR-A independent mechanism, 
unlike ANP (Winquist et al., 1984). Thus, initial characterization of KNP 
showed it was a weak vasodilator compared to ANP which required 
endothelium derived vasoactive factors to exert this action. 
Previous studies have shown that infusion of supraphysiological doses of ANP 
results in marked reduction of BP (Kleinert et al., 1986). This lowering of BP 
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is due to decreased, stroke volume, heart rate, peripheral resistance and 
increased excretion of water. Our experiments on effect of KNP on vascular 
and renal parameters suggest that KNP does not seem to follow the paradigm 
of NPs. It was evident that KNP infusion resulted in reduction in cardiac 
output as it lessened heart rate. But KNP seems to affect these parameters in a 
sustained manner in contrast to the prompt recovery seen in the case of ANP. 
Further, KNP did not have any significant renal effect which was a striking 
difference between the two peptides. 
To understand the differences between KNP and ANP, a structure-based 
activity assessment gave some insight to this non-classical activity. KNP ring 
functioned as a classical NP, with 10 fold lower potency compared to ANP. 
The lower activity of Ring could be attributed to two important features of the 
ring. The two D substitution in place of G at positions 8 and 19 and the lack of 
C-terminal NSFRY sequence similar to ANP. The crystal structure of ANP 
with NPR-A indicates that G residues (9, 20) at equivalent positions fall in the 
vicinity of E169A and E169B of the receptor (Figure 3.10). On replacement of 
this G with D as in case of Ring might cause an electrostatic repulsion, which 
could result in lower potency. Further, receptor binding studies have shown 
that ANP loses its affinity to NPR-A on deletion of the C-terminal extension. 
This fact is supported by the information from the crystal structure. Residues 
N24, S25, F26 and R27 of the C-terminal extension of ANP form a β-sheet 
with Q186 B and F188 B of the receptor along with a hydrogen bond between 
N24 of ANP with E187 B. KNP ring lacks these interactions with two basic 




 Interestingly, Helix relaxed aortic strip in an endothelium dependent manner 
with comparable activity to that of full length. This showed that KNP has two 
pharmacologically active segments, which induced vasorelaxation by distinct 
mechanisms. Although both the segments have equipotent activity comparable 
to that of full length, putative helical segment of the tail seemed to contribute 
to the action of KNP. The vasorelaxant ability of R&H was in agreement with 
that observed for KNP. The presence of the helical segment attributed function 
to R&H as well as KNP in an endothelium dependent manner. Further, Δ 
Helix showed much lower aortic strip dilation abilities compared to full length 
which was not influenced by endothelium. 
Similar observations were obtained when intracellular cGMP levels were 
measured in response to activation NPR-A by different ligands. Ring elicited a 
10 fold lower activity compared to ANP. In comparison to ANP, KNP, Δ 
Helix and R&H showed a 300 fold lower potency in elevating cGMP levels in 
the cells. This showed that the presence of any segment of tail of KNP lower 
the binding ability of the ring. In other words, tail segment of KNP was 
redirecting the otherwise functional ring away from the NPR. These results 
were conclusive to show that despite the presence of a functional NP ring, 
KNP lacks classical NP like functions due to its C-terminal tail.  
In an investigation to obtain insights into the molecular players of KNP 
evoked vasorelaxation, endothelium derived vasoactive factors namely NO, 
prostacyclin and hyperpolarization seem to influence KNP’s vasodilatory 
properties. KNP and Helix did have alteration in their vasodilatory properties 
in the presence of different inhibitors. Although all three factors seem to 
influence the activity of the peptides, inhibition of NO production lead to 
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complete loss of function. Hence, looking at the possible mechanisms through 
which NOS is activated might lead us to understand the exact molecular 
target. Endothelial NOS is activated by pathways that increase intracellular 
calcium. This increase in Ca
2+
 is dependent either on IP3 and DAG or Gq 
protein when different receptors are activated (Furchgott, 1984). Further, 
direct potassium channel openers have shown to increase intracellular calcium 
(Busse et al., 2002; Sheng et al., 2009; Strobaek et al., 2004). Hence, 
sequential inhibition of  phospholipase C (enzyme that produces IP3 and 
DAG), Gq protein activation, different classes of potassium channel (Calcium 
activated-, voltage gated-, ATP dependent- potassium channels)(Busse et al., 
2002) and monitoring the vasodilatory properties of Helix and KNP will 





               
 
Figure 2.18.  Proposed mechanism of action of KNP 
A non- classical NP like KNP binds to an unknown receptor or ion channel on endothelium using to tail to evoke NO, prostacyclin and 
potassium ion mediated hyperpolarization. These factors cause the relaxation of the underlying vascular smooth muscle. KNP functions 
through its tail despite the presence of the functional ring. 
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Thus with this study we have been able to propose a mechanism of action of 
KNP. A classical NP like ANP will bind to NPR on both endothelium and 
vascular smooth muscle to elevate cGMP to cause vasodilation. While KNP, a 
non-classical NP, binds to a unknown target receptor or ion- channel on 
endothelial cells and produces NO, prostacyclin and K
+
 hyperpolarization to 
cause relaxation of the underlying smooth muscle cells using its tail, despite 
the presence of a functional ring. Thus, KNP’s tail wags its ring (Figure 2.18). 
In-vivo the activity of KNP seems to be the contribution of both the 
pharmacophores. It may be speculated that KNP may be proteolytically 
cleaved to produce both the functional segments and hence an additive effect 
of both the segments is observed as KNP’s activity. Further, the presence of a 
long tail may increase the PK of KNP. 
Although the present experiments does not confirm the processing of KNP, it 
is evident that one particular segment of KNP does not contribute to its entire 
activity.  Further, neither KNP nor its truncations had any renal effects. 
Despite being able to bind to NPR-A like ANP, Ring did not cause diuresis 
which was an intriguing observation. In the past, alternately spliced variant of 
BNP was shown to have renal effects while lacking vascular functions (Pan et 
al., 2009). The presence of the D residues in place of conserved G at positions 
3 and 14 of the ring may alter the conformational plasticity of the receptor 
which dictates the physiological response. Thus, we speculate that the 
conformational changes for the receptor activation may be altered in the case 

































Chapter 3:  The ring of resistance- KNP ring is 
resistant to degradation 
3.1. Introduction 
Natriuretic peptides are involved in regulating key physiological functions and 
hence an appropriate level of the peptides has to be sustained in circulation so 
as to exhibit necessary activity. Release and clearance of NPs play major roles 
in regulating plasma concentrations of NPs. Physiological stimuli such as 
atrial wall stretch increases NP levels in the blood stream and multiple 
clearance mechanisms render the peptide inactive. Among the various 
processes involved in degradation of NPs; receptor mediated internalization 
and proteolytic hydrolysis of the peptides have major roles. 
NPR-C is involved in active clearance of NPs by receptor mediated 
endocytosis and degradation. It is a promiscuous receptor that binds to all 
three mammalian NPs with relative affinities ranked as CNP=ANP > BNP. 
The crystal structure of the three NPs with NPR-C shows that the receptor 
provides a rigid molecular interface for ligand binding. The lack of 
conformational plasticity in the receptor binding pocket renders the NPs to 
adopt different receptor bound conformations to overcome the entropic 
penalties. Due to the different local shape the NPs take up when they are 
bound to the receptor, they utilize different interaction surface on NPR-C (He 
et al., 2006). Further C-terminal residues of ANP and BNP in complex with 
NPR-C seem to be more solvent accessible compared their NPR-A bound 
conformation (Ogawa et al., 2004). It may be inferred for these facts that, 
NPR-C provides a fixed volume binding pocket, which accommodates the ring 
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residues of all NPs. Hence, the residues of NP ring play key role in altering the 
affinities of the peptide to NPR-C. 
The second major route of clearance of NPs are by proteolytic degradation by 
neutral endopeptidase (NEP), a zinc- dependent membrane bound 
mettaloprotease. It cuts at the N-terminus of hydrophobic residue which is C1-
F2 bond in case of NPs, rendering in disruption of the ring structure. 
Hydrolysis potency of the NPs in-vitro may be ranked as CNP = ANP > BNP, 
which is ascribed to their structural difference. Present studies show that size 
of NP is a factor that attributes NEP resistance. Peptides with long N- terminus 
and C-terminus tails are less prone to hydrolysis. It is thought that NP with 
longer tails cannot be accommodated within the binding pocket due to spatial 
constraints the tail would impose. In accordance with this theory, peptides 
with long tails like urodilatin and DNP have higher resistance to degradation 
compared to BNP. Thus, the residues in the N-terminus and C-terminus of a 
NP influence its susceptibility to NEP, but there is no knowledge about the 
contribution of residues within the ring of NP.  
With the understanding that the molecule of our interest, KNP had a varied 
biological effect compared to other NPs, we wanted to understand the stability 
of this peptide to degradation. With the prior knowledge, we predicted that 
KNP with the longest tail among the NPs known may have high resistance to 
proteolysis. Further the Ring of KNP has substitutions in position 3 and 14 
where a conserved G is replaced by D. Apart from these changes the Ring has 
more polar residues in comparison to ANP. With these differences in sequence 
of Ring, we hypothesized that Ring KNP might have higher resistance to 
hydrolysis.  Hence, our study focused on understanding the half life of KNP 
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and its Ring. The experiments were designed to look the overall in-vitro 
degradation of KNP and its ring by both NEP and NPR-C. 
3.2. Materials and Methods 
3.2.1. Materials 
Most the materials used in the experiments are as described in chapter 2. Apart 
from thelready mentioned chemicals, Recombinant NEP (Sino biological, 
Shangai, China) and KNP mutants rings (Genescript Corporation, NY, USA) 
 
3.2.2. Synthesis of KNP, ANP, Ring, Ring mutants and K-ANP 
KNP was recombinantly expressed and purified as described in Chapter 2. 
Ring and ANP were synthesized using F-moc based manual SPPS and purified 
as described in Chapter 2.  
3.2.3. Degradation of NPs with recombinant purified NEP 
10 µM of respective NPs or mutant NPs were mixed with of 1 µg/µl BSA in 
50 mM HEPES buffer containing 150 mM NaCl, 5 mM MgCl2 at pH 7.4. A 
peptide aliquot was withdrawn before the addition of NEP, and this served as 
zero time point. The peptide mixture was pre-incubated at 37°C for 5 min 
before the addition of NEP. Recombinant NEP dissolved in 50 mM HEPES, 
150 mM NaCl, 5 mM MgCl2, pH 7.4 at 0.1 µg/μl concentration and stored at -
30°C until used for assay. An aliquot of the enzyme was thawed on ice and 2 
μl NEP per 50 μl reaction volume was added to bring the final concentration 
of NEP to 4 ng/µl and a time chase experiment was conducted. At time points 
5 min, 15 min, 30 min (90 min and 150 min for KNP), an aliquot (100 µl) of 
the NEP-NP mixture was withdrawn and the reaction was terminated by the 
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addition of 2 µl of 1 M HCl to every 100 µl of reaction mixture. After the 
complete time chase experiment was completed, 51 µl from each time point 
was used for degradation profiling by LC-MS and rest 51 µl was used for in-
vitro half-life determination. 
3.2.4. Degradation profiling by LC-MS 
The aliquot of NP-NEP mixture that was sampled from every time point was 
neutralized with 1 µl of 1 M NaOH. Following the neutralization, NEP-NP 
mixture was reduced using 100 mM DTT (final concentration) and the final 
volume was increased to 100 µl. The samples were run on reversed- 
chromatography followed by ESI-ion trap mass spectrometer to analyze the 
degradation products. 70 µl of the samples were injected and the separation 
was performed on Thermo scientific Hypersil Gold column (C18, 3 µm, 2.1 X 
30 mm) using 0.1% FA as buffer A and 0.1% FA with 80% Acn as buffer B. 
The methodology began with sample injection followed by column wash for 5 
min (flow rate 200 µl/min). During wash, elute from the column was 
redirected to waste. Following the wash, a simple gradient 0-50 % B in 30 min 
was used to separate the fragments of the NPs generated during degradation. 
During the gradient, elute from the column was linked to ESI source which 
was set which following parameters for elute to ionize: Sweep gas flow rate: 
30 ARB, Auxillary gas flow rate: 5 ARB, Spray voltage: 4.5 kV, Capillary 
temperature: 350°C, Capillary voltage: 9 V. The ion-trap detector was set in 
the positive mode with mass/charge range 500-2000. The total ion count 
generated over the entire gradient was analyzed to determine the degradation 
pattern. The mass spectrum was reconstructed using Pro-mass X-calibur 
software to obtain the mass of the peptide fragment. Using Expasy- protparam 
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tool, the possible peptide fragment molecular weights were calculated, which 
aided the identification of the exact lytic bond. Five independent trials have 
been performed for each peptide to confirm the degradation pattern. 
3.2.5. Cell culture and transfection 
The cells were grown and transfected by the procedure described in chapter 2. 
3.2.6. Ability of Ring mutants to activate NPR-A 
The method performed is as described in chapter 2. 
3.2.7. In-vitro half life determination 
The peptide aliquots were neutralized with 1 µl of 1 M NaOH. Peptide final 
concentration equal to 100 nM ANP, 1 µM Ring, 300 nM GRG, 1 µM K-ANP 
and 2 µM DRG from the NEP-NP mixture were incubated with the cells 
transfected with NPR-A. Prior to treatment with peptides, the transfected cells 
were washed with PBS and treated with 150 µl of 0.5 mM IBMX containing 
basal vascular growth media without FBS for 30 min. The peptide aliquots 
from different time point were added to pre- incubated cells to a final 
concentration as indicated and further incubated at 37°C in 5% carbon-di-
oxide atmosphere for 30 min. After the incubation, the peptide containing 
media was aspirated and 150 µl of 0.1 M HCl was added to the cells. The 
plates were incubated with shaking at 50 rpm at room temperature for 30 min. 
The cell lysates were collected and assayed for intracellular cGMP levels 
using Enzo life science cGMP ELISA kit. Manufacturer’s protocol was 
followed to perform the assay. The whole cell protein concentration was 
measured by BCA assay to normalize the obtained cGMP response. 
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3.2.8. cGMP response in cells co-transfected with NPR-A and NPR-C 
Transfection procedure was same as prescribed in chapter 2, but changes in 
changes in DNA concentration. NPR-A and NPR-C plasmid were taken in 1:2 
ratio. Per well 0.5 µg of NPR-A and 1 µg NPR-C plasmids were transfected 
using 2.5 µl lipofectamine 2000
TM
. In control population of cells, 0.5 µg of 
NPR-A and 1 µg empty pCMV-4 vector was transfected. 





3.3.1. Stability of KNP and ANP to NEP mediated proteolysis 
Previous studies have shown that NPs with long C- or N- terminal extensions 
were resistant to NEP mediated proteolytic digestion. Hence, we wanted to 
evaluate if KNP with the longest C-terminal tail among the known NPs was 
resistant to hydrolysis. ANP was used as the control for the experiment. The 
peptides incubated for different time points were reduced and separated on 
liquid chromatography linked to mass spectrometer to analyze the degradation 
product. Further, peak area of the maximum intense ion of the peptide was 
used for determining the relative amount of peptide remaining at a time point. 
ANP was markedly degraded within 5 min incubation.  The degradation 
products showed similar profile as previously reported. The lytic bonds were 
assessed based on the molecular weight. This was in accordance with a study 
that identified the cleavages sites as C1-F2, R5-M6, R8-I9, G10-A11 and G14-
L15 (Vanneste et al., 1988) with C1-F2 being the first bond to be cleaved.  In 
contrast incubation of KNP with NEP did not show any difference in the ion 
count all through the experimental time point (150 min) and no degradation 
products were detected. This experiment showed that KNP was completely 




             
Figure 3.1. KNP is resistant to degradation 
LC-MS degradation profiling of A- ANP and B- KNP is as shown. The peptides were incubated with purified NEP for indicated amount of 

























































































3.3.2. Sequence analysis of Ring 
KNP was resistant to NEP hydrolysis. Although previous studies would 
suggest that the length of C-terminal tail of KNP would confer resistance to 
NEP, we wanted to look at the influence of residues within the ring of KNP to 
hydrolysis. The sequence of Ring was compared to the NPs about which the 
susceptibility to hydrolysis is previously known, namely; ANP, BNP, CNP 
and DNP. Apart from the residues which are conserved between the NPs, Ring 
has two D residues at position 3 and 14 that have replaced normally conserved 
G’s in ANP, BNP and CNP. Other residues within the Ring are common to 
either BNP or DNP. It is also interesting to note that at positions 10, 11, 12 
and 14, Ring had polar residues while other NPs have a combination of polar 
and hydrophobic residues. As mentioned in the introduction, NEP cleaves 
peptide bonds at the N-terminus of hydrophobic residues. Hence, we 
hypothesized that the Ring of KNP might have higher resistance to 
degradation than the ring structures of other NPs. Moreover, Ring had only 
two residues in its C-terminal tail, second shortest, next to CNP. Hence, it 
would serve as a good model to look at the influence of residues within the 
ring on hydrolysis of NPs. 
 
Figure 3.2. Ring of KNP is a chimera of BNP and DNP ring with unique 
substitutions 
Sequence of NPs whose degradation ability is previously studied was aligned. Yellow 
residues are conserved in all NPs. Pink residues are common between Ring and BNP. 
Grey residues are common between Ring and DNP. Blue residues are unique to Ring.  
CNP    -GLSKGCFGLKLDRIGSMSGLGC----------------- 
ANP    -LRRSSCFGGRMDRIGAQSGLGCNSFRY------------  
DNP    EVKYDPCFGHKIDRINHVSNLGCPSLRDPRPRPNAPSTSA  
Ring   -GLLISCFDRRIDRISHTSDMGCRH---------------  
BNP    MVQGSGCFGRKMDRISSSSGLGCKVLRRH-----------  
 
1      3 4                           12   14       17
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3.3.3. Degradation pattern of Ring vs ANP 
It is of interest to note that Ring had 5 residues in the N-terminus and 2 
residues in C-terminus which are shorter compared to ANP (6 residues in N-
terminal and 5 residues in C-terminus). The stability of Ring was assessed by 
incubating the peptide with NEP for the indicated periods. Using LC coupled 
with MS, the cleavage pattern and the relative quantities of uncleaved peptides 
were compared with those of ANP. The degradation pattern of Ring was 
similar to that of ANP. Cleavage sites within the ring were mapped to be C1-
F2, R5-I6, and R9-I10. But no cleavage was detected between D14-L15. 
Although the lytic bonds were similar, we observed that C1-F2 might not be 
the only peptide bond to be cleaved as the reaction begins. The degradation 
pattern showed the presence of peptides with mass 1225.3 Da and 1563.3 Da 
which corresponded to N-terminal and C-terminal peptide segments when R8-
I9 bond was cleaved.  This observation suggested that R8-I9 was cleaved in 
equal proportion as C1-F2 as the reaction began. In the cleavage pattern of 
ANP the masses of all the peptide fragments showed that they were derived 
after the NP was cleaved at C1-F2. This observation suggested that NEP has 
difficulty recognizing the conserved lytic bond C1-F2 of Ring as the reaction 
begins, although it is cleaved eventually. 
Further, Ring seemingly degraded slowly compared to ANP. The intensity of 
the parent ion of Ring (indicated by the black arrow in Figure 3.3.B) 






        
 
Figure 3.3. Ring degrades slower but at similar positions compared to ANP 
LC-MS profiling of degradation products of A- ANP and B- Ring is as shown. The parent ion indicated by the black arrow, reduces slower in 
case of Ring. The lytic bonds are similar between ANP and Ring. Arrows of the same color in Ring degradation profile indicates same 



























































































































3.3.4. In- vitro half life of ANP and Ring 
 
Since, the degradation of Ring seemed slower than ANP, the in-vitro half life 
of these peptides were evaluated based on its activity. To assess its activity, 
peptides treated with NEP for indicated amount of time were tested for their 
ability to evoke cGMP response in CHO-K1 expressing NPR-A. ANP showed 
a marked decrease in its activity by 5 min. The half- life of ANP was about 1.8 
min. This value matched with the previously reported values for ANP 
(Stephenson and Kenny, 1987). Ring on the other hand showed an extended 
half-life of 12 min (Figure 3.4). This remarkable increase in half-life (about 
6.5 times higher than ANP) suggested that residues within the ring of KNP 
had great influence on the degradation of the peptide. 
The results obtained so far show that Ring of KNP has increased resistance to 
hydrolysis and is not cleaved in the same manner as ANP although the lytic 
bonds were similar. Hence, based on the previously described model for NEP 
hydrolysis (Chapter 1, section 1.7.2), we hypothesized that the presence of D3, 
R4 apart from D7, R8 might mislead the peptide into an improper orientation 
within the binding pocket. Since the peptide is cleaved at the conserved 
position as ANP, it is evident that the peptide can place itself in the right 
position but it requires more time to do so. It could be postulated that the 
presence of two DR sites of the Ring of KNP places the peptide in two 
different spatial orientations which are in equilibrium (Figure 3.5). The 
process of switching the conformation delays the metabolism of the ring. 
Further we observe that Ring was not hydrolyzed at position D14-L15 as 
ANP, which suggested that D residue at position 14 had some influence on 
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hydrolysis. Hence, we wanted to understand if D3, R4, D14 have influence on 
hydrolysis. To investigate this hypothesis we designed mutant Rings of KNP. 
 
Figure 3.4. Ring has 6.5 fold higher half-life compared to ANP 
Peptides incubated with NEP for the indicated time points were treated with cells 
transfected with NPR-A. The relative cGMP produced during different time points 
were calculated with t = 0 as the baseline (100%). The half-life of ANP was 
calculated to be 1.8 min and that of Ring was 12 min. 





Figure 3.5. Hypothetical model for degradation of Ring 
The presence two DR sites on the sequence of Ring misguides the peptide to orient 
the lytic bond in a wrong position. Thus, the peptide has to switch its conformation to 
be hydrolyzed. This process delays the metabolism of the Ring. Red line indicates the 





























3.3.5. Design of Ring mutants 
Mutant rings with D3, R4 and D14 sequentially replaced by G as in the case of 
ANP. Ring mutant GRG, with both D3 and D14 would typically resemble 
BNP ring without C-terminal tail. Mutant DGD had R4 replaced by G. Third 
mutant had D14 replaced by G, called DRG. Finally G residue at 3, 4 and 14 
of ANP ring was replaced with D, R and D. This peptide was called K-ANP. 
These mutants were designed to understand the influences of residues within 
the ring on hydrolysis. 
                        
Figure 3.6. Design of Ring mutants 
Residues at positions 3, 4 and 14 of Ring were sequentially swapped with the residue 
of ANP at that particular position to generate the mutants. 
 
3.3.6. Degradation profile of Ring mutants 
Similar to Ring and ANP, the degradation pattern and susceptibility were 
determined by profiling the degradation products on LC-MS. The lytic bonds 
were similar to that of Ring. Complete N-terminal and C-terminal peptide 
fragments of R8-I9 cleavage were absent in GRG and DGD, while these 
peptides were detected for DRG. This observation suggested that the presence 
D3 and R4 residue in the ring influenced the orientation of C1-F2 peptide 
bond in the active pocket of NEP. K-ANP showed similar cleavage pattern 
like ANP but was cleaved at an uncommon location between R4-R5. Cleavage  
         3’4’           14’  
ANP    CFGG--DR-AQS-G--C 
BNP    CFGR--DR-SSS-G--C 
RING   CFDR--DR-HST-D--C 
GRG    CFGR--DR-HST-G--C 
DGD    CFDG--DR-HST-D--C 
DRG    CFDR--DR-HST-G--C 





Figure 3.7. Degradation profile of GRG and DGD Ring mutants 
LC-MS profiling of degradation products of A- GRG and B- DGD is as shown. The lytic bonds of both the peptides are similar to Ring but 
the rate of disappearance of the parent ion (indicated by black arrow) is faster than Ring. Same arrow color in Ring degradation profile 



















































































































            
 
Figure 3.8. Degradation profile of DRG and K-ANP 
 
LC-MS profiling of degradation products of A- DRG and B- K-ANP is as shown. The lytic bonds of both the peptides are similar to Ring but 
the rate of disappearance of the parent ion (indicated by black arrow) is faster than Ring. Same arrow color in Ring degradation profile 



































































































at R5-I6 was not detected for K-ANP. Further, there was no hydrolysis 
detected between D14-L15 for all the mutants.  
GRG seemed to degrade faster like ANP in comparison to Ring. While DRG, 
DGD and K-ANP seemed have an intermediate degradation rate between 
GRG and Ring. These results evidently suggested that D3 and R4 residues 
influence the spatial orientation of the peptide in NEP binding pocket which 
renders its cleavage at uncommon sites, thereby delaying metabolism. Since 
the degradation profiling suggested that the residues under consideration 
altered the rate of hydrolysis, we assessed the in-vitro half-lives of the 
mutants.  
3.3.7. Ability of Ring mutants to bind to NPR-A 
 
In order to evaluate the in-vitro half life of Ring mutants, the potency of these 
mutants to evoke cGMP response in NPR-A transfected CHO-K1 cells was 
required. The concentration to be tested for determining the half-life was 
chosen based on the potency of the peptide.  
GRG showed an increased ability to activate NPR-A compared to Ring. This 
peptide’s potency could be considered equivalent to that of BNP (Kambayashi 
et al., 1990; Nakao et al., 1991). DGD mutant lost its ability to evoke cGMP 
response by ~ 30 fold compared to native ring. The capabilities of GRG and 
DGD to activate NPR-A suggests that certain molecular interaction with the 
receptor is enhanced in the absence of both D residues, while the presence of 
R9 orients the peptide in a position that prevents this unfavorable interaction. 
The ability of DRG to induce cGMP response was lesser compared to Ring, 
while the activity was significantly improved compared to DGD. This 
Residue positions indicated in this chapter refer to common 17-residue NP ring 
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observation could be explained with the crystal structure of ANP with NPR-A. 
G3 and G14 residues are in the vicinity of E169A and E169 B of receptor at a 
distance of 5.7 Å and 4.4 Å respectively (Figure 3.10). Thus replacement of G 
with D might introduce electrostatic repulsion in these locations. However, the 
presence of R9 residue seems to improve the interaction with the receptor. 
Further K-ANP, which has ring with substitution at positions G3, G4 and G14 
with D, R and D showed equivalent potency as that of Ring, which was 10 
fold lower compared to ANP. This observation confirmed the fact that despite 
the presence of C-terminal tail of ANP, K-ANP did not elicit equipotent 
response as ANP, which is attributed to D3, R4 and D14.  
 
Figure 3.9. D3, R4, D14 within the Ring influences NPR-A activation 
Ring mutants were evaluated for the amount of cGMP produced when treated with 
NPR-A transfected CHO-K1 cells. Each data point is an average of 3 independent 






































Figure 3.10.  D3 and D14 within the ring may cause electrostatic repulsion 
on NPR-A binding 
Crystal structure of ANP- NPR-A shows that G3 and G14 are in the vicinity of E169 
residue of the receptor. Replacement of G to D might cause electrostatic repulsion.  
 
 
3.3.8. In-vitro half life of Ring mutants 
GRG mutant showed similar half-life as ANP, suggesting both the D residues 
have influence on degradation. The half life of DGD was not evaluated owing 
to its low potency. DRG Ring was more prone to hydrolysis compared to 
native Ring, but had 3 times higher resistance compared to ANP. Further, K-
ANP showed 4 fold increased half-life by compared to ANP. These results 
suggested that residues within the ring of a NP played crucial role in 
influencing their hydrolysis. The residues D3, R4 and D13 seem to confer 
resistance to the peptide. These results also support our hypothesis that the 
presence of two DR sites places the peptide in two different conformations 
within the binding pockets, which delays its metabolism. Although further 
modeling is required to understand the placement of the D14 in the active site, 
one may observe that this residue as well plays important role in decreasing 
the peptide’s sensitivity to degradation. 
 




Figure 3.11. D3, R4, D14 residues influence the half-life of NP ring 
Peptides incubated with NEP for the indicated time points were treated with cells 
transfected with NPR-A.  
Each data point is an average on 3 independent trials and is represented as mean ± 
SEM.  
 
3.3.9. Ability of Ring to evoke cGMP response in the presence of NPR-C 
NPR-C is a promiscuous receptor which binds to all NPs. The relative 
difference in affinity of the NPs to NPR-C is attributed to the side chains of 
amino acid residues within the ring. Among the different interaction sites on 
NPR-C available for NP binding, the pocket that accommodates residue 12 of 
NP ring seems to contribute to the lack of selectivity of this receptor. Position 
12 of the ring is occupied by either a hydrophobic residue or a polar residues 
among different NPs (M in CNP, Q in ANP, V in DNP and S in BNP), which 
fit in the same binding pocket. This pocket of NPR-C is composed of 
hydrophobic residues F119, Y126, A96, A116 and F170 (Figure 3.12). Thus, 
interaction of a hydrophobic residue is more favored. KNP Ring has T in 






























BNP. Moreover, two D residues (3 and 14) substitution to G have larger side 
chains to be accommodated.. Thus the hypothesis was NPR-C a receptor with 
rigid ligand interaction interface conformation and Ring of KNP with bulkier 
substitution in its sequence compared to other known NPs, might have less 
NPR-C binding ability. 
To test this hypothesis, CHO-K1 cells were co-transfected with NPR-A: NPR-
C in the ratio 1:2. The cGMP response of these cells on treatment with ANP or 
Ring was compared to cells which were transfected with NPR-A: pCMV4 
empty vector (1:2). The dose dependent cGMP response of ANP in population 
of cells which are expressing both NPR-A and NPR-C was 100 fold lower 
compared to the population of cells with equivalent expression of only NPR-
A. While Ring showed a difference of 10 fold lower ability to evoke cGMP in 
the presence of NPR-C. This was a preliminary experiment conducted and will 
be repeated. The data is the average value of two independent trials. However, 
this preliminary data suggests that Ring has lower NPR-C binding ability 
compared to NPR-A. 
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Figure 3.12. Binding pocket of residue 12 of NP with NPR-C 
The binding pocket is composed of hydrophobic residues which accommodates both 
polar and non-polar side chains of residues in position 12 of NP ring. 
 
 
                      
Figure 3.13. Ring has lower ability to bind to NPR-C 
Preliminary results of the ability of the peptides to evoke cGMP response in cells 
expressing both NPR-A and NPR-C are as shown. A- ANP, B- Ring.The data points 
























































3.4. Discussion  
Rapid degradation of NPs, necessitate higher dose infusions to harness their 
therapeutic potential. Previous studies have shown the size of a NP as an 
indicative factor of its susceptibility to degradation. Increasing the lengths of 
N- and C-terminal extensions of NPs increases half-life (Dickey and Potter, 
2011). The primary processes involved in the degradation are protease 
mediated hydrolysis and receptor- mediated endocytosis. 
The protease involved in NP metabolism is NEP, an ubiquitous enzyme which 
is involved in degradation of a number of vasoactive peptide hormones such as 
angiotensin II, endothelin, vasopressin and many others. Inhibition of NEP in-
vivo has resulted in increased plasma levels of NPs, suggesting its influential 
role in the degradation of NPs (Wegner et al., 1995). Previous studies have 
shown that the susceptibility of NPs to hydrolysis is proportional to the 
decreasing lengths of C- and N- termini extensions. A recent study by Pankow 
et al., has proposed a model illustrating the mechanism of NEP mediated 
hydrolysis by docking NP into the active site of NEP. This model has 
exemplified the possible role on longer N- and C- termini tails of NPs in 
conferring resistance to hydrolysis. The authors suggest that the resistant NPs 
with longer extensions have difficulty to slip into interior cavity of the enzyme 
which does not allow them to orient correctly. In correlation with the known 
information, KNP was completely resistant to NEP mediated hydrolysis until 
150 min (experimental period of the study).  
However, no information about the influence of residues within the ring upon 
degradability of NP has been previously reported. Our investigation on the 
vulnerability of Ring (only Ring of KNP) to degradation has resulted in 
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insights about the influence of residues within the NP ring. Ring of KNP 
showed a 6.5 fold increase in half-life compared to ANP despite its shorter C-
terminal extension. Although the degradation pattern was similar, the residues 
within the Ring altered the preferred peptide bond for cleavage. This 
observation led us hypothesize that the orientation of KNP ring within the 
pocket of NEP is misguided in the presence of two DR residues within the 
sequence.  
The creation of Ring mutants were D3, R4, D14 in KNP Ring have been 
sequentially replaced by G to mimic ANP, aided in the understanding the 
influence of these residues on NPR-A activation and NEP hydrolysis. The 
replacement of R4 to G while retaining both D residues, rendered the peptide 
to lose 30 fold activity when compared to native Ring, while replacement of 
both D residues to G while retaining R4 increased its ability to activate NPR-
A. From the NPR-A- ANP complex crystal structure it was evident that G3 
and G20 were in the vicinity of E169A and E169B of the receptor. These facts 
suggested that R4 of Ring aided the placement of both the D residues away 
from their actual pockets which are negatively charged. This observation was 
further strengthened as the incorporation of D3, R4 and D20 into ANP ring 
(K-ANP) resulted in 10 fold loss in its ability to activate NPR-A similar to 
Ring in comparison to ANP. 
The degradability of these mutant Rings implied that D3, R4 and D20 have 
crucial roles in conferring resistance to degradation. K-ANP showed an 
increased half-life 4 times longer than ANP, which further elucidated the role 
of these residues. We observe that inclusion of D, R, and D extended the half-
life of ANP but not as long as Ring, which could be attributed to other 
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residues within the ring. A sequence comparison between different NPs show 
that position 10, 11, 12 and 13 of KNP- Ring was occupied by polar residues 
which are probably not recognized by NEP which cleaves a hydrophobic 
residue. BNP has polar residues in all these positions while ANP, CNP and 
DNP have a combination of polar and hydrophobic residues. Among these 
residues position 12 of the NP ring is variable position. This position is 
occupied Q in ANP, S in BNP, V in DNP, M in CNP while T in Ring. Thus 
evaluating the role of the residue at position 12 could potentially increase the 
half-life of NPs. Thus, the investigation of residues within the Ring of KNP 
has shed light on possible role of residues within the ring to confer resistance. 
Following the study on NEP mediated hydrolysis of Ring, we concluded a 
preliminary study conducted on the preference of Ring to bind to the clearance 
receptor. Structural studies on NPR-C show that the receptor offers a rigid 
scaffold for ligand interaction. The peptides adopt their local structure to fit 
into a fixed volume available in the binding pocket. Our groundwork 
experiment which assessed the cGMP response of ANP and Ring in cells 
expressing both NPR-A and NPR-C was indicative that Ring of KNP had 
lower ability to bind to NPR-C in comparison to ANP. This may be attributed 
to the bulky amino acid replacements in Ring of KNP compared to ANP 
which would require larger volume for accommodation into the NPR-C 
binding pocket.  
Thus far, all known previous studies have shown that longer the N- and C-
termini extension of NP better is its resistance to hydrolysis. Our study has 
extrapolated the information known about the structural requirements of a NP 
to have increased stability. With Ring of KNP as the model, we have 
 123 
 
demonstrated that residues within the ring of NP have influential role in 
conferring higher stability to both the processes of degradation that are equally 
involved in the clearance of NPs. Further incorporation of the identified 
residues into ANP ring, improved its stability, which puts forward the 










































































Chapter 4: Lessons from KNP 
4.1. Conclusions 
This thesis focuses on the mechanisms of action and clearance of a unique NP-
like peptide; KNP which was initially identified from the partial cDNA library 
Bungarus flaviceps venom gland. KNP is composed of 60 amino acid residues 
protein with a 5 residue N-terminal extension, 17- residue conserved NP ring 
and 38 residue long C-terminal tail. Sequence and structural analysis of KNP 
showed that the C-terminal tail has a unique sequence which does not match 
with any known sequences in the non-redundant database. Also the last 21 
residues of the C-terminal tail has propensity to form an α- helix, a distinctive 
feature not known in any other NPs. Ring of KNP had two substitutions at 
position 3 and 14 where a conserved G residue was replaced by D. These 
differences in the sequence and structure of KNP are pivotal in modulating 
KNP bioactivity. 
To elucidate the mechanism of action of KNP, this protein was recombinantly 
expressed in E.coli and purified by various chromatographic methods. KNP 
was tested for its activity using in-vivo, ex-vivo and in-vitro assays. KNP was 
able to relax aortic strips with intact endothelium with lower potency 
compared to ANP, but had no significant relaxant effect on aortic strips which 
were denuded of endothelium. This finding established that KNP acts via an 
NPR-independent mechanism to elicit vasorelaxation. 
In anesthetized rats, infusion of ANP or KNP dropped blood pressure, but in 
distinctly different patterns. ANP caused a quick drop in blood pressure which 
recovered in a short time. In contrast, KNP caused a continuous drop in blood 
pressure which persisted throughout the experimental period. Further animals 
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infused with ANP showed remarkable diuresis while there was no renal  
response to KNP. These results conclusively showed that KNP was a non-
classical NP. 
 Different deletion and truncation mutants of KNP were designed based on its 
predicted structure to understand its non- canonical activity. Ring of KNP 
behaved exactly like a classical NP with lower potency while the putative 
Helix exhibits an identical response to KNP (i.e. equivalent potency) on 
endothelium-denuded and intact aortic strips. Further deletion of the putative 
helical segment from KNP diminished its activity significantly.  
 
 
Figure 4.1. KNP- A non-classical NP 
 
 
Two pharmacologically active segments
Putative-helix functions like full length KNP
Ring functions like classical NP
Functions in an endothelium- dependent manner
KNP prolongs reduction in blood pressure and 
heart rate with no renal effects
Ring reduces blood pressure like ANP with no renal effects
KNP is resistance to NEP mediated hydrolysis
Ring has higher resistance to proteolysis compared to ANP
Residues D3, R4, D14 within the ring confer its resistance
D
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These observations demonstrated that KNP has two pharmacologically active 
segments namely; ring and helix. Helix contributed to the activity of KNP. 
Further on cells expressing NPR-A, Ring was able to produce a dose-
dependent cGMP response. But the ability of the ring to bind to NPR-A was 
significantly lost in the presence of the C-terminal tail of KNP. Thus, the C-
terminal tail of KNP seemed to confer its biological action while redirecting 
its ring away from the NPR. 
Using specific inhibitors for endothelium dependent vasorelaxation pathway, 
nitric oxide, prostacyclin and hyperpolarization factor were shown to be 
necessary to mediate KNP and helix signaling. From these observations, KNP 
can be classified as a non-classical NP, which functions via its C-terminal tail 
to evoke endothelium-dependent vasorelaxation despite the presence of a 
potentially functional NP- ring.  
Although in-vitro and ex-vivo establish the role of C-terminal tail in 
conferring the entire function to KNP, infusion of different truncations of KNP 
in experimental rats, showed that the in-vivo activity of KNP may be a 
combination effect of both the pharmacophores.  
Following the characterization of biological action of KNP, its resistance to 
degradation was evaluated. KNP had a remarkable resistance to degradation (> 
150 min) when incubated with NEP, a major enzyme involved in the clearance 
of NPs. The Ring of KNP had two substitutions of evolutionarily conserved 
residue (G at position 3 and 14 were replaced by D). Ring showed an 
increased half-life which was 6.5 times greater compared to ANP. Sequential 
mutations of selected residues with the Ring of KNP to G showed that D3, R4 
and D14 were key residues which conferred resistance to Ring degradation. 
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Studies prior to this have main focused on improving half-life of NPs by 
increasing their size by addition of longer N-terminal and C-terminal tails. 
This study pinpoints the importance of residues within the ring of NPs to 
influence degradation. Further, as a proof of concept, incorporation of D3, R4 
and D13 in the ring of ANP demonstrated that the half-life of mutant K-ANP 
increased to 4 times higher than ANP.  
Thus, the studies described in this thesis presents several interesting 
observations  contributing to the understanding of NPs and open up avenues 
for further research on KNP and the NEP resistant Ring of KNP. 
4.2. Future Perspectives 
4.2.1. Immediate prospects 
 The first part of the study encompassed in this thesis describes the bioassay-
determined actions KNP while the second part illustrates KNP’s resistance to 
degradation. There are important further questions to be addressed in both the 
sections as follows: 
4.2.1.1. Identification of the molecular target of Helix 
 
As seen from the results described, Helix of KNP has no sequence similarity 
to any known peptides. We know that Helix requires NO, prostacyclin and 
hyperpolarization factors to cause vasodilation. It is evident that Helix is a NO 
stimulator. Hence, to identify the molecular target, the vasodilatory response 
of Helix may be evaluated in the presence of different inhibitors upstream of 
the identified mediators such as phospholipase C inhibitors, Gq protein 
inhibitors, potassium channel inhibitors. 
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4.2.1.2. In-vivo half-life of K-ANP 
 
Through in-vitro experiments, K-ANP has been shown to have a longer half-
life, although its potency is lowered compared to ANP. From a therapeutic 
perspective, ANP is associated in potent hypotension and short half- life. ANP 
with D3, R4 and D14 incorporated in the ring, called K-ANP is a less potent 
NP with longer half-life, pharmacologically desired characteristics. Hence, 
would be of great interest to look at in-vivo activity of K-ANP. 
4.2.2. Big Picture 
In spite of high activation of NP system during heart failure, the increased 
levels of circulating ANP and BNP are inadequate to counter the 
neurohormonal activation which leads to high sodium retention and 
congestion (Lee and Burnett, 2007a). Nevertheless, further elevating the 
circulating levels of ANP or BNP by intravenous infusion has bioactivity and 
reduces cardiac load, plasma renin levels together with increased natriuresis 
and diuresis. The discovery of different NPs from endogenous (alternately 
spliced BNP, familial mutation in ANP) and exogenous source (snake venom) 
has aided the creation of chimeric NPs which have potentially improved 
pharmacological characteristics. In order to gain insight into the therapeutic 
potential of a NP, there is necessity to evaluate its pharmacodynamic 
properties in larger animal models (Both normal and with heart failure). 
4.2.2.1 Influence of KNP on hemodynamic parameters in larger animal 
models 
 
To understand the therapeutic potential of KNP, its effect of hemodynamic s 
and renal parameters has to be evaluated in larger animal models. 
Pharmacodynamics of a number of NPs have been assessed in both dogs and 
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sheep models. Hence, similar dosages of KNP may be evaluated in both 
anesthetized and conscious healthy animals. Further, KNP can be evaluated on 
animal models with heart failure. These models may help predict the 
efficiency of KNP in human heart failure. 
4.2.2.2. Development of NEP resistant NP 
 
The second part of this thesis has increased understanding of the role of 
residues within the NP ring in conferring resistance to hydrolysis. Further 
research is necessary to identify other potential residues within the ring which 
influence the peptide’s degradability. Incorporation of these residues in NP 
will result in increased half-life of the peptide which would lessen the 
necessary dosage of NP infusions and potentially increase the pharmacological 
efficacy of NPs in patients with hypertension. 
4.2.2.3. Metabolism of KNP in-vivo 
 
The present findings show that both the pharmacophore seems to be 
contributing to the in-vivo activity of KNP. Further, in-vitro and ex-vivo 
experiments have conclusively shown the presence of the tail prevents the ring 
from binding to NPR. Hence, one probable explanation to these observations 
is the metabolism of KNP in-vivo. KNP might be proteolytically cleaved 
which renders both the segments to function. Hence, in-vivo cleavage products 
to KNP can be assessed using mass-spectrometric analysis of plasma samples 
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Figure A.2. Experimental setup for measurement of blood pressure and urine output in anesthetized rats (de Bold et al., 1981) 
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